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MARK4 (MAP/Microtubule Affinity-Regulating Kinase 4) belongs to a family of serine-threonine 
kinases phosphorylating Microtubule Associated Proteins, causing their detachment from the 
microtubules (MTs) and thus increasing MTs dynamics. MARK proteins show high homology with 
PAR complex proteins family, involved in assessing cell polarity during embryogenesis, epithelial 
morphogenesis, neural differentiation, and cell migration. MARK proteins are thus implied in 
several processes involving MT network: cytoskeleton dynamics, cell polarity, centrosomes 
formation, chromosomal segregation, cytokinesis.  
The MARK4 gene (19q13.2) encodes at least two alternatively spliced isoforms, L and S, 
differentially expressed in human tissues. MARK4S is the predominant isoform in normal brain and 
post-mitotic neurons. MARK4L has been found up-regulated in glioma cell lines and neural 
progenitors, as well as in hepatocarcinoma cell lines, suggesting a role in cell proliferation. The 
dual nature of MARK4 isoforms has been pinpointed by their expression profile in glioblastoma-
derived cell lines and neural stem cells (NSCs), other than glioma, and the balance of the two 
isoforms, favouring the L splicing variant in glial tumors, is being investigated as a potential target 
of dysregulation in gliomagenesis. A linked view is whether the predominant expression of 
MARK4L, isoform of a gene involved in the microtubule dynamics, may concur to mitotic errors 
during gliomagenesis. 
Both isoforms of MARK4 have been found associated to centrosomes and midbody, in glioma as 
well as in normal cells, suggesting that the kinase might have a role in all phases of the cell cycle. 
Moreover, MARK4L showed an additional nucleolar localization in glioma, raising the idea that, in 
tumors, the L variant has isoform specific functions and interactions with nucleolar components. 
To verify the functional impact of MARK4 gene in glioma and in normal cells and to define the role 
of MARK4S and L isoforms with respect to their subcellular localization, we set up a functional 
study by RNA interference in glioblastoma (GBM) cell lines and normal fibroblasts, with specific 
silencing of both MARK4S and MARK4S+L. 
We showed that MARK4 depletion determines heavy alterations in the cell shape of both G-32 
GBM cell line and fibroblasts, corroborating MARK4 implication in cytoskeleton organization, and 
in accordance with the known role of MARK proteins in MTs dynamics. 
MARK4 silencing particularly affected the centrosome cycle. Silenced G-32 GBM cell line and 
fibroblasts presented most of cells with the duplicated centrosome, apical to the nucleus, as 
typical of G1/S transition, while differently, control cells displayed centrosomes in all phases of the 
centrosome cycle. Accordingly, after MARK4 silencing, cell cycle analysis showed in both tumor 
Abstract 
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cells and fibroblasts, an increase of G1 cells fraction and a strong reduction of mitoses, most of 
which displayed aberrations of spindle poles. These findings indicate that MARK4 depletion targets 
the G1/S transition checkpoint, probably knocking down a positive regulator.  
It is worth noticing that the observed alterations of cell morphology, centrosome and cell cycle 
progression, and of mitosis were more pronounced when silencing MARK4S+L, as if the depletion 
of the sole MARK4S might be partially compensated by MARK4L, being both isoforms localized at 
centrosomes and midbody. 
MARK4 silencing on nucleoli revealed that the L isoform of MARK4 is not a specific marker of 
tumor (glioma) cell lines, in fact it was also detectable in fibroblasts. However, MARK4 depletion 
showed a nucleolar pattern different in G-32 GBM cells from that of fibroblasts: G-32 showed, 
after both anti-MARK4S and MARK4S+L siRNA, a pronounced intensity of MARK4L signal in several 
nucleoli, while some others appeared silenced. In contrast, silenced fibroblasts showed, 
particularly after anti-MARK4S+L siRNA, several nucleoli unlabelled with MARK4L. It’s currently 
unknown the molecular basis for this difference which may be more than a quantitative one due 
to the higher levels of MARK4L in the nucleolar compartment of tumor cells where it’s generally 
upregulated. 
The concomitant alterations of both centrosomal and nucleolar compartments highlighted by 
MARK4 silencing raise the hypothesis of a MARK4 role in the regulation of the Nucleus - 
(Nucleolus) - Centrosome (NC) axis. NC - axis is oriented and paired with the polarization and 
migration axis of many cell types, including fibroblasts and neural cells. Microtubules act as major 
actors in organizing a dynamic structure along NC - axis, regulating nuclear movement during cell 
migration and polarization. Since MARK4 cooperates with the microtubule network, its depletion 
may interfere with the correct orientation of the NC – axis. 
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1. MARKS (MAP/MICROTUBULE AFFINITY-REGULATING KINASES) 
MAP/Microtubule affinity-regulating kinases (MARKs) are a serine-threonine kinases family 
responsible for phosphorylation of Microtubule Associated Proteins (MAPs) including Tau, MAP2, 
MAP4 and doublecortin. MARKs-mediated phosporylation causes MAPs detachment from 
microtubules, resulting in increased MTs dynamics and favouring MTs instability and disassembly 
[Drewes 1997, Matenia 2009].  
MARK kinases are members of AMPK (AMP-activated protein kinases) family, subfamily of the 
Ca2+-calmodulin dependent protein kinases (CAMK) [Bright 2009].  
Orthologs of MARK kinases are described in lower eukaryotes, such as Par-1 (partition-defective) 
in Caenorhabditis elegans and KIN1/KIN2 in S. pombe [Elbert 2005]. PAR proteins are known to 
cooperate in cellular polarization, interacting with microtubule dynamics and several other cellular 
processes [Pellettieri & Seydoux 2002]. 
The human genome contains four functional MARK4 genes: MARK1, MARK2 (EMK1), MARK3 (C-
TAK1) and MARK4 (MARKL-1), mapping on human chromosomes 1, 11, 14 and 19 respectively 
[Espinosa 1998], plus 30 pseudogenes (www.itb.cnr.it/kinweb/pseudogene.php). 
 
1.1 MARKs STRUCTURE 
MARKs have a highly conserved structure consisting of six sequence segments, as other AMPK 
kinases [Marx 2010] (Figure 1). 
 
spacerUBA COOHNH3
CD KA1
catalytic domain
 
Figure 1: schematic representation of MARK protein structure. Boxes are not drawn to scale. 
 
N-terminal header  
The N-terminal sequence is usually different for each protein of the family: its role is still unknown. 
 
Catalytic domain  
MARKs catalytic domain has the typical bi-lobate structure of protein kinases. The larger carboxy-
terminal lobe (~ 170 residues) is mostly α-helical, while the smaller amino-terminal lobe (~ 80 
residues) consists mainly of β-strands with a single α-helix. The two lobes define the cleft of the 
active site, for substrate and ATP, consisting of a P-loop (phosphate-binding loop), a catalytic loop, 
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and a T-loop (activation loop, containing a conserved consensus sequence, LDTFCGSPP, where 
threonine and serine residues work as phosphorylation targets). This structure is very flexible, 
allowing conformational changes responsible for activation/inactivation. The catalytic loop 
contains a RD motif consisting of a highly conserved, catalytically active aspartate, preceded by an 
arginine residue, assumed to interact with the primary phosphorylation site of the T-loop.  
The T-loop is anchored to the base of the active site: in the inactive state, the T-loop is partially 
disordered and folded into the cleft, blocking the access of substrates and ATP. When MARK 
proteins are activated by T-loop phosphorylation, the catalytic site becomes accessible, leading 
the protein to exert its kinase activity.  
The P-loop assists the γ-phosphate transfer to the substrate phosphorylation site [Timm 2008].  
 
Linker  
The linker is a negatively charged motif, resembling the Common Docking (CD) site of MAP kinases 
and possibly binding interactors or co-factors. 
 
UBA domain  
This small and globular domain is homologous to Ubiquitin-Associated proteins but differently and 
peculiarly folded: probably the MARK UBA domain, instead of binding ubiquitin, interacts with 
MARK catalytic domain (in its N-terminal lobe) locking it in an open (inactive) conformation. Two 
different functions were proposed for MARK UBA domain:  
 autoinhibition: locking the kinase in an open conformation, the UBA domain prevents 
substrate and ATP binding [Panneerselvam 2006]; 
 positive regulation: the open conformation favours the access of activating/deactivating 
kinases to the activation loop [Murphy 2007]. 
Based on these hypotheses, depending on both the phosphorylation state of the kinase domain 
and cofactors interactions, the UBA domain may play functions of inhibition, activation and 
stabilization[Marx 2010]. 
 
Spacer  
This is the most variable region among the MARK members, likely with a regulatory role, since it 
holds phosphorylation sites targeted by aPKC1. 
                                                          
1 Atypical Protein Kinase C 
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The C-terminal tail (KA1 domain)  
The Kinase-Associated (KA1) domain (~ 100 aminoacids) is characterized by a N-terminal 
hydrophobic and concave surface, surrounded by conserved and positively charged residues: this 
motif may be the binding site for negatively charged regions of cytoskeletal proteins, MARK 
catalytic domain, or MARK CD domain, probably with an autoinhibitory function [Tochio 2006]. 
This view is sustained by evidences reported for yeast KIN1 and KIN2 and for Snf1-pKD (an AMPK 
protein from Schizosaccharomyces pombe): Snf1 C-terminal region is an autoinhibitory domain 
(AID) binding both the N-terminal and C-terminal lobes of the kinase domain, reducing its mobility 
[Chen L. 2009]. Also in yeast, the C-terminal tail physically interacts with the N-terminal kinase 
domain (presumably in its open conformation) with an autoinhibitory effect [Elbert 2005].  
The KA1 domain has been also reported to be involved in protein localization [Tochio 2006].  
 
1.2  MARKS REGULATION  
MARK kinases are regulated through multiple pathways, as summarized in Figure 2 [Matenia, 
2009]. In general, as above mentioned, MARK activation increases microtubule dynamics, while its 
inhibition stabilizes microtubules. 
Phosphorylation events in the catalytic domain of MARK can enhance or reduce kinase activity. 
Additionally, MARK activity can be positively or negatively modulated by interaction with other 
proteins. 
 
 
Figure 2 schematic representation of MARK interactions/regulation ( from Matenia 2009) 
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ACTIVATION BY PHOSPHORYLATION 
Liver Kinase B1 (LKB1) and MARK-Kinase (MARKK) activates MARK proteins by phosphorylation on 
the threonine residue in the T-loop (MARK1 T215; MARK2 T208; MARK3 T211; MARK4 T214). 
Similarly, the activated Calcium/calmodulin-dependent protein kinase I (CaMKI) binds and 
phosphorylates MARK2 within its kinase domain, but at different sites [Matenia 2009].  
 
 INHIBITION BY PHOSPHORYLATION 
Glycogen Synthase Kinase 3β (GSK3β) negatively regulates MARKs proteins by phosphorylating a 
serine residue located near the threonine activation site in the T-loop (MARK1 S219; MARK2 S212; 
MARK3 S215; MARK4 S218). The inhibitory effect occurs independently from the phosphorylation 
status of the threonine, since the phosphorylated serine is no longer able to stabilize, by 
interactions with other aminoacids, the activating loop. The inhibitory phosphorylation by GSK3β 
even overrides previous activation by MARKK or LKB1 at T208 [Timm 2008].  
Mammalian aPKC (required for cell polarity together with MARK2) down-regulates MARK2 by 
phosphorylation in its spacer domain (T595), enhancing MARK capability to bind 14-3-32 protein, 
and thus promoting the dissociation of MARK2 from the lateral membrane in polarized cells. 
The human PIM1 kinase, a downstream effector of many cytokine-signalling pathways, associates 
with and phosphorylates MARK3, leading to a substantial decrease in kinase activity [Suzuki 2004, 
Hurov 2004, Matenia 2009]. 
 
INHIBITION BY INTERACTION 
14-3-3 proteins (Par-5 homologues) bind MARK kinases in their catalytic domain [Benton 2003] or 
in the spacer (after MARK phosphorylation by aPKC), downregulating MARKs activity and 
modifying their localization, probably by stabilizing the inhibitory interaction between KA1 domain 
and the aminoterminal or the catalytic domain.  
PAK5 (p21-activated kinase) inhibits MARK2 by interaction with its catalytic domain [Matenia 
2005].  
Also ubiquitin and MARK UBA and KA1 domains are able to interact with MARK kinasic domain 
with inhibitory effects.  
                                                          
2 phospho-serine/phospho-threonine binding proteins that interact with many partners and regulating different biological 
processes. 
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Very recently, 4 synthetic compounds (sharing a 9-oxo-9H-acridine-10-yl as functional group) have 
been designed to inhibit MARK activity [Timm 2011]: these compounds are capable to overcome 
the toxicity due to MARK2 overexpression in neurons (causing microtubule breakdown, with 
alteration of cells shape, which look rounded and reduced in size).  
 
 INHIBITION BY DIMERIZATION  
Dimerization, a common event for kinases, is a candidate mechanism for MARK autoinhibition: 
MARK proteins are able to crystallize as dimers, linked by covalent disulfide bridges between T-
loops. This conformation (open state) ends in MARK inhibition which is marked by the activation 
loop folded into the cleft to lock it. Currently no direct in vivo evidences of this interaction are 
available [Marx 2010]. 
 
1.3 MARKs LOCALIZATION AND FUNCTION 
MARK1, MARK2 and MARK3 are known to localize in the cytoplasm, where they associate with the 
intracellular microtubule network [Drewes 
1997]. Differently, MARK4 associates to 
centrosomes and the midbody [Trinczek 2004, 
Magnani 2009]. 
According with their localization and role as 
regulators of MAPs/microtubule affinity, MARK 
kinases are implicated in several cellular 
processes involving the microtubule network as 
depicted in Figure 3: cytoskeleton dynamics 
[Schneider 2004], centrosome formation, 
chromosomes segregation in mitosis and 
cytokinesis [Fukasawa 2002]. Interestingly 
some of the cellular processes involving MARK 
activity are characteristic of neurons physiology 
and some pathologies, such as Alzheimer’s 
disease and tumours.  
  Figure 3 Overview of the role of MARK family kinases in 
cellular processes (from Matenia 2009) 
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MICROTUBULE-DEPENDENT TRANSPORT AND ENDOCYTOSIS 
MARK proteins are involved in regulation of microtubule-dependent transport, (i.e. in axons): 
more specifically, MARK2 regulates this process by phosphorylating MAPs, which are known to 
interfere with motor proteins responsible for organelle, vesicle and protein transport [Mandelkow 
2004].  
A similar role in endocytosis has been demonstrated: MARKs co-localize with clathrin, and act as 
regulators of microtubule-dependent transport of clathrin-coated vesicles (CCV) [Schmitt-Ulms 
2009].  
 
EMBRYONIC DEVELOPMENT AND CELL POLARIZATION 
Par-1 homologues in C. Elegans and Drosophila play a role in establishing polarity: they 
accumulate asymmetrically in the embryo, inducing asymmetric division and axis polarization, 
which are essential for a correct embryonic development [Tomankak 2000]. KIN1 and KIN2 
homologues in Schizosaccharomyces pombe show a similar role in cell polarization, since they are 
responsible for the bipolar growth leading to the typical yeasts rod-shape [Drewes 2003].  
Accordingly, an asymmetric localization of MARK proteins, together with aPKC and Par-5 (14-3-3), 
characterizes epithelial and neuronal cells polarization in mammals [Bohm 1997; Matenia 2009].  
MARK2, in particular, has a role in polarized neurite outgrowth and maintenance of neuronal 
polarity in mammalian cells, which requires dynamic instability of microtubules. Indeed, 
overexpression of MARK2 in CHO3 cells leads to microtubule disruption and consequently to cell 
shrinking and death: the effect can be counteracted by using microtubule stabilizers (such as taxol) 
or by synthetic compounds specifically inhibiting MARK activity [Drewes 1997, Timm 2011]. In 
accordance, the overexpression of inactive MARK2 disturbs the polarity in mammalian epithelial 
cells and inhibits axon formation. Conversely, reduction of MARK2 expression by RNA interference 
(RNAi) induces multiple axons in hippocampal neurons [Biernat 2003, Chen 2006, Terabayashim 
2007]. Similarly, MARK2 is involved in the reorganization of the microtubule network during 
epithelial differentiation of liver and kidney cells [Cohen 2004]. 
Interestingly, Helicobacter pylori CagA protein mimics MARK substrate, thus interacting with 
MARK/Par-1: binding the catalytic loop of the kinase, CagA inhibits kinase activity [Nesic 2010], 
leading, in gastric carcinomas, to the disorganization of the gastric epithelial structure [Saadat 
2007] and spindle misorientation with mitotic delay [Umeda 2009].  
                                                          
3 Chinese hamster ovary 
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NEURONAL MIGRATION 
Microtubules dynamics is essential for proper neuronal migration. Phosphorylation by MARK 
proteins of doublecortin (a MAP highly enriched in leading processes of migrating neurons) 
modifies its affinity for microtubules, affecting the motility of neurons [Schaar 2004] and, in the 
developing mouse cortex, MARK2 knockdown determines failure of neurons migration beyond the 
intermediate zone [Sapir 2008].  
Interestingly, knockdown of MARK2 in mice influences other physiological processes, such as 
fertility, homeostasis of the immune system, memory, growth and metabolism [Bessone 1999; 
Hurov 2001; Hurov 2007; Segu 2008].  
 
CELL CYCLE, CELL SIGNALLING AND SUBCELLULAR LOCALIZATION CONTROL  
MARK3 phosphorylation of Cdc25 phosphatase induces its binding to 14-3-3, inhibiting Cdc25-
mediated activation of Cdc2/cyclinB complex, and thus blocking mitosis initiation [Peng 1998]. In 
addition, Pim-1 phosphorylation and inhibition of MARK3 promote cell cycle progression at the 
G2/M phase [Bachmann 2004].  
MARK3 also regulates Ras-MAPK pathway, by phosphorylation of KSR14 and induction of 14-3-3 
binding [Muller 2001]. 
Finally, MARK3 regulates class IIa Histone Deacetylases (HDACs) subcellular localization: 
phosphorylation of 14-3-3 binding sites on HDACs prevents the interaction with 14-3-3 proteins, 
responsible for HDACs nuclear exclusion (following MARK3 phosphorylation, HDACs are instead 
retained in the nucleus) [Dequiedt 2006]. Similarly, phosporylation by MARK3 mediates PKP25 
nuclear retention, by activating its 14-3-3 binding site [Muller 2003].  
 
MARK4 specific expression and localization in glioma, a group of tumors that have been 
extensively charaterized in our laboratory, is discussed further on in detail. 
 
 
                                                          
4 Kinase Suppressor of Raf-1 
5 Plakophilin 2 
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1.4 MARKs IN HUMAN PATHOLOGIES 
Hyperphosphorylation of Tau (a MAP highly expressed in the Central Nervous System) is a key 
hallmark of Alzheimer disesase (AD): it can be induced by MARKs, CDK5 and GSK3 kinases, with 
consequent alteration of Tau localization and proteolytic cleavage [Drewes 2004].  
Cleaved hyperphosphorylated Tau is thought to accumulate in neuron somatodendritic 
compartments: by aggregating into paired helical filaments, hyper-P-Tau forms insoluble 
neurofibrillary tangles, characteristic of Alzheimer’s disease (together with loss of synapses and 
neurons) [Chin 2000; Gamblin 2003]. A role for MARK proteins in this neurodegenerative 
pathology has been suggested by MARKs co-localization with neurofibrillary tangles [Chin 2000] 
Furthermore hyperphosphorylated Tau, enhanced kinases activity (including MARKs) and 
breakdown of microtubules are commonly found in the missorted dendritic regions with 
Alzheimer disease progression [Zempel 2010]. The location of MARK4 gene close to the locus of 
susceptibility (ApoE) to AD (Trinczek 2004) is an additional hint. 
Considering a different aetiological model, Tau phosphorylation is not the initiating event but a 
consequence of β-amyloid aggregation [Chatterjee 2009], which causes transport defects (due to 
increase and bundling of microtubules) and improper distribution of Tau into the somatodendritic 
compartments [Zempel 2010]. 
Further support for a possible role of MARKs/MAPs in Alzheimer’s disease is provided by the 
finding that MARK2 activation in the early steps of pathogenesis can rescue transport mechanisms 
and synapses [Thies 2007]. 
 
The MARK1 gene, overexpressed in the prefrontal cortex of post-mortem brain tissues from 
autistic patients, is a candidate autism susceptibility gene as appointed by the significant 
association of several SNPs within the gene with the disease.  
MARK1 involvement in the regulation of synaptic plasticity [Jeon 2005] and in cognition has been 
suggested to be responsible for subtle changes in dendritic functioning [Maussion 2008]. 
Interestingly, MARK1 gene is localized within a fragile site (FRA1H) and its expression levels are 
significantly altered in tumour-derived cell lines [Pelliccia 2007]. This datum together with MARK1 
silencing by methylation in primary gastric cancers [Yamashita 2006] and its up-regulation in lung 
carcinoma [Sun 2004] makes plausible a role of MARK1 in neoplastic transformation . 
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2. MARK4 (MAP/MICROTUBULE AFFINITY-REGULATING KINASE 4) 
 
MARK4 gene (19q13.2) consists of 18 exons. At least two MARK4 isoforms are known (Figure 4): 
 MARK4S (Short) mRNA (3609 bp) consists of 18 exons and encodes a 688 aa6-protein 
whose predicted MW7 is 75.3 kDa; 
 MARK4L (Long) mRNA (3529 bp) derives from exon 16 skipping and the consequent shift of 
the reading frame, leading to the production of a 752 aa-protein with a predicted MW of 
82.5 kDa.  
MARK4 sequence shares 55% homology with other MARKs (90% in the catalytic domain). Both 
MARK4 isoforms maintain the characteristic protein structure of MARK family previously 
described, with a N-terminal catalytic domain, a CD domain, the UBA domain, a wide spacer region 
and the C-terminal tail. The main phosporylation sites in the the T-loop of the catalytic domain are 
T214 and S218.  
As a consequence of the alternative splicing, the two isoforms differ in the C-terminal tail: MARK4L 
includes, as other MARK proteins, the KA1 domain, whereas MARK4S contains a domain with no 
homology to any known structure [Espinosa 1998], suggesting different functions for the two 
isoforms. MARK4 C-tail domain folds in a conformation similar to those of MARK1, 2 and 3, 
suggesting a similar autoinhibitory and interactive function [Marx 2010].  
 
Figure 4 [top] schematic 
representation of MARK4 exons 
and respective protein domains; 
[bottom] alternative splicing of 
exon 16 gives origin to MARK4 
isoforms. MARK4S RNA includes 
exon 16 (right): the STOP codon 
is inside exon 18 and MARK4S 
protein lacks the KA1 domain. 
With exon 16 skipping, the stop 
codon is shifted forward: 
MARK4L protein is longer and has 
the classical KA1 domain (right). 
Boxes are not drawn to scale. 
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2.1 MARK4 REGULATION and INTERACTION 
MARK4 is regulated similarly to other MARK members. 
LKB1 phosphorylates T214 in the T-loop, activating MARK4 [Lizcano 2004; Brajenovic 2004].  
It has been demonstrated that MARK4 is polyubiquitinated and interacts with the deubiquitinating 
enzyme USP9X [Al-hakim 2008]. As non-USP9X-binding mutants of MARK4 are hyperubiquitinated 
and not phosphorylated at T214, it is likely that polyubiquitination inhibits LKB1 activation of 
MARK4. This model implicates that, in the steady state, MARK4 UBA domain is ubiquitinilated and 
does not interact with the catalytic domain, making the T-loop less accessible to LKB1. 
Alternatively, ubiquitin may mask T214 site or induce conformational modifications favouring the 
activity of phosphatases [Al-hakim 2008]. 
It has also been established that MARK4 interacts with aPKC [Brajenovic 2004] and could therefore 
be phosphorylated and inactivated by this kinase, as reported for MARK2 and MARK3 [Hurov 
2004]. 
 
Tandem Affinity Purification and Immunoprecipitation experiments led to the identification of at 
least twenty putative MARK4 interactors, of which PKCλ8 and Cdc42 are implicated in cell polarity 
control and TGFβIAF9 is thought to be hortolog of Miranda, a protein involved in the asymmetric 
division of neuroblasts in Drosophila. MARK4 interacts with 14-3-3 protein (14-3-3η isoform) 
known to control many cellular processes by binding phosphorylated proteins (possibly direct 
regulators of MARK4 itself) and also interconnecting different pathways. ARHGEF2, a cytoskeleton 
binding protein, and Phosphatase 2A, associated with microtubules and Tau regulator, are 
indicated as putative MARK4 interactors [Brajenovic 2004; Angrand 2006].  
Exogeneous MARK4 protein was also found to co-purify in a protein complex containing α, β, and γ 
tubulin, non-muscle myosin and actin [Trinczek 2004; Brajenovic 2004]. 
As previously mentioned, MARK4 interacts with LKB1 and aPKC kinases and with the 
deubiquitinating enzyme USP9X.  
 
2.2  MARK4 EXPRESSION  
MARK4L was initially identified as one of the overexpressed transcripts in hepatocarcinoma cells, 
characterized by inactivation of the Wnt/β-catenin pathway and β-catenin accumulation in the 
                                                          
8 Protein Kinase C lambda 
9 Transforming Growth Factor β-Inducing Anti-apoptotic Factor 
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nucleus, suggesting it might be a downstream component of the Wnt-signalling pathway, 
potentially involved in hepatocellular carcinogenesis [Kato 2001]. 
Northern Blot and semi-quantitative competitive PCR on different organisms (human, rat and 
mouse tissues) showed that MARK4 gene is ubiquitously expressed, with particularly elevated 
levels in brain and testis. In detail, MARK4L was found highly expressed in testis, brain and also in 
kidney, liver and lung [Trinczek 2004; Schneider 2004; Moroni 2006], while MARK4S levels were 
found elevated in testis, heart and brain [Kato 2001; Moroni 2006].  
MARK4S was instead found rapidly and transiently up-regulated after an ischemic event in brain, 
mainly at the hippocampus, together with many other genes overexpressed in the injured brain (if 
compared to the healthy counterpart), including LKB1. Induced overexpression of MARK4S in 
hepatocytes leads to a reduced cell vitality, suggesting that MARK4S up-regulation in the early 
stages of an ischemic event might increase the probability of neuron death [Schneider 2004]. 
 
MARK4 IN HUMAN GLIOMA 
CYTOGENOMICS AND EXPRESSION DATA 
MARK4 gene maps at 19q13.2 locus, centromeric to the Loss of Heterozigosity (LOH) area in 
gliomas the most common and malignant tumours in the Central Nervous System (CNS), 
[Hartmann 2002]. By characterizing the chromosomal rearrangements affecting the 19q13 region 
in gliomas and by array-CGH analysis, we found that MARK4 was never deleted in these tumours. 
Conversely it was duplicated in one glioblastoma cell line (MI-4) and a BAC clone of the gene was 
found included in a “gain” region in a few tested glioma cell lines *Roversi 2006, Magnani 2009+.  
In an attempt to describe in detail these findings, MARK4 expression has been widely investigated 
in glioma by different approaches. By semi-quantitative PCR, MARK4L splicing variant resulted up-
regulated in 58 samples including cell lines and tissue gliomas, and in human neural progenitor 
cells, and down-regulated during glial differentiation into astrocytes, suggesting a role for the 
kinase in proliferating and undifferentiated cells. Conversely, MARK4S was found highly expressed 
in normal brain and hardly detectable in glioma and neural progenitors [Beghini 2003]. Since 
MARK4S expression level was observed to increase during neuronal differentiation this isoform 
was delineated as a neuron-specific marker in the CNS.  
Immunohistochemistry revealed nonetheless that both MARK4L and S proteins were expressed in 
neurons of the grey matter (whereas the white matter was unlabeled) suggesting that both forms 
play a general role in neural tissues [Moroni 2006].  
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Recently, by sequencing analysis we ruled out mutations (see below) as the cause of the sustained 
expression of the MARK4L variant in glioma and demonstrated by real-time PCR, immunoblotting 
and immunohistochemistry that both MARK4 isoforms are co-expressed in 21 glioma cell lines and 
36 tissue samples of different malignancy grades. MARK4L is confirmed as the predominant 
isoform, whereas MARK4S transcript levels are significantly decreased in comparison and have an 
inverse correlation with malignancy grade. The switch towards MARK4L was also observed in 
glioblastoma-derived cancer stem cells (GBM CSCs) and neural stem cells (NSCs) suggesting that 
the balance between the MARK4 isoforms is carefully guarded during the normal neural 
differentiation program, but may be subverted during gliomagenesis. We hyphotesized that 
MARK4 alternative splicing may be the most likely mechanism regulating MARK4L and S balance. 
By immunohistochemistry MARK4L, but not MARK4S, was detected in cells of the subventricular 
zone in human and mice [Magnani, In press].  
 
2.3  MUTATION ANALYSIS 
Mutations in protein kinase genes are often implicated in cancer initiation and development, since 
most kinases are involved in cell proliferation. Most of the activating alterations occur inside the 
catalytic domain, including the ATP-binding site.  
Only a few MARK4 sequence changes are reported in the literature: 
 A splice-site mutation (exon 13 +1 G>A; spacer region) identified in one glioblastoma sample (among 
91 GBM samples analyzed) [The Cancer Genome Atlas Research Network 2008].  
 5 MARK4 alterations identified in a panel of 210 different human cancers investigating 518 protein 
kinase genes [Greenman 2007]:  
- two missense mutations in two colorectal adenocarcinomas: 
exon 12 (R377Q and R418C; spacer region);  
- two silent mutations in multiple tumour samples  
exon 5 (Y137Y)  
exon 9 (I286I) (kinase domain);  
- one intronic mutation in a lung cancer specimen 
exon 8 +5 C>T; (kinase domain);  
 
In patients affected by Peutz-Jeghers Syndrome, typically characterized by LKB1 mutations, no 
MARK4 mutations have been found [de Leng 2007].  
 
Background 
 
 
17 
Mutation analysis of MARK4 has been performed in our laboratory, by screening MARK4 exons 
pointed out by the literature as possible targets of mutation (exons 5, 8, 9, 12, 13) and functionally 
relevant regions, such as the kinase domain (exons 2-10), the ubiquitin-associated (UBA) domain 
(exons 10-12) and exon 13.  
Direct sequencing of the coding regions and flanking regulatory sequences on a panel of glioma 
cell lines and tissue samples of different malignancy only revealed a synonymous substitution in a 
GBM cell line (c1101G>C variation in exon 11) which does not affect the splicing process, as 
confirmed by cDNA analysis. 
Also intron retention between exons 3-4, 5-6 and 11-12 was tested, but no splicing errors were 
detected. 
Since MARK4 mRNA undergoes alternative splicing (exon 16 is skipped in MARK4L) the entire 
fragment between exons 15 and 17 has been analyzed, showing a yet unreported single 
nucleotide alteration, c1878-61G>A, in several samples (both cell lines and tissues): this change 
however does not affect the splicing process [Magnani, In press]. 
 
2.4 SUBCELLULAR LOCALIZATION 
Recently, MARK4L localization in glioma cell lines, assessed by Immunofluorescence (IF), showed 
multiple localization sites of the endogenous protein. MARK4 kinase, under microtubule-stabilizing 
conditions, associated to normal and aberrant centrosomes, observed particularly in glioblastoma 
cell lines, and in the midbody as demonstrated by γ-tubulin co-localization [Magnani 2009]. 
This result confirms previous data referring to MARK4 protein conjugated to GFP (green 
fluorescent protein) showing co-localization with microtubules and interphase centrosome of CHO 
and neuroblastoma cell lines [Trinczek 2004]. 
Furthermore, we could establish that the centrosome association was not abolished by 
nocodazole-induced depolymerization of microtubules, suggesting that MARK4L is a core 
component of centrosomes. Moreover, under standard IF conditions, MARK4L associated with the 
nucleolus, as confirmed by nucleolin counterstaining. These IF results have been validated by 
immunoblotting in centrosomes, nucleoli and midbody fractions [Magnani 2009].  
 
Recently, by IF, we provided evidence that also the MARK4S isoform, like MARK4L, associates with 
the centrosome and midbody, but it is not detectable in the nucleolus of glioma cell lines. In 
normal cells, including human neural progenitors, adult fibroblasts and myoblasts, we found that 
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both MARK4 isoforms are undetectable in the nucleoli, but associate to the centrosome and 
midbody as previously observed in glioma cell lines [Magnani 2009]. Furthermore, MARK4L 
showed a nucleolar localisation in glioblastoma (GBM) derived cancer stem cells (CSCs), but not in 
neural stem cells (NSCs). Thus the nucleolar association appears to be a specific feature of the L 
isoform, and a definite feature of glioma cells. An association of MARK4L with nucleolar RNAs or 
ribonucleoprotein has been suggested since RNAse treatment of GBM cells disrupts the nucleolar 
localisation of MARK4L and nucleophosmin, one of the major structural component of nucleoli 
[Magnani, In press]. 
 
The relevant features of Centrosome, Midbody and Nucleolus are summarized further on. 
 
BOX 1 – MARK4 POSITIVE SUBCELLULAR COMPARTMENTS 
Centrosome  
Centrosome is a primary MTOC (MicroTubule Organizing Center), thus capable to nucleate and organize 
microtubules, localized in the cytoplasm, adiacent to the nucleus without any delimitating membrane 
[Fukasawa 2002]. Two distinct domains are distinguishable in the centrosomal structure: 
 the centriolar domain including centrioles, cylindrical organelles responsible for centrosome 
 organization and replication. Each centriole consists of 9 triple microtubules; 
 the pericentriolar domain an accumulation of many fibers and proteins surrounding the centriole, 
 responsible for microtubules nucleation, mediated by association of α and β-tubulin dimers on a γ-
 tubulin ring [Doxsey 2001].  
The centrosome has important functions in both interphase and mitosis, devoted to the organization of the 
cytoskeleton (and thus regulating cell polarity, adhesion and motility) and the mitotic spindle [Kramer 
2002]. Centrosome is also involved in many different cellular processes, such as cell cycle progression, 
cytokinesis, cellular response to stress and signal transduction [Doxsey 2005, Martinez-Garay 2006]. 
Centrosome replication is strictly regulated during cell cycle, specifically occurring during G1/S transition 
and in S phase, to ensure the formation a bipolar spindle at mitosis (Figure 5). 
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Figure 5 Centrosome duplication cycle, modified from Nigg 2002 
 
Alterations in centrosome number, structure and function (typically observed in tumours) can lead to the 
formation of aberrant multipolar spindles, and consequently to errors in chromosome segregation, thus 
causing chromosomal instability (CIN), a hallmark of many tumours. 
 
Midbody  
At the end of the mytotic process, with cytokinesis, in correspondence of the midzone, a contractile ring of 
actin and myosin determines the approaching of the two opposite surfaces of the membrane and their 
merging and closing, causing the separation of the two daughter cells [Bringmann 2005].  
The two daughter cells are initially connected by a narrow intercellular bridge, whose core is the midbody, 
consisting of microtubules and a dense matrix [Mullins 1982]. The diameter of the intercellular bridge 
progressively decreases until vanishing, so that the two daughter cells are effectively separated. The 
midbody, finally discarded, undergoes degradation [Mullins 1977].  
The midbody is thought to have an important role in maintaining a bipolar spindle and in correctly 
separating the cytoplasm between the two daughter cells. 
 
Nucleolus  
The nucleolus is a subnuclear structure not delimited by membranes mainly functioning as the “ribosome 
factory of the cell”. In mammalian cells the nucleolus is disorganized in prophase and reassembled at the 
end of mitosis concomitantly with restoration of rDNA transcription at the level of competent Nucleolus 
Organizing Regions (NOR), clusters of genes (rDNA), coding for ribosomal RNA (rRNA), located on the short 
arm of acrocentric chromosomes 13, 14, 15, 21 and 22. In immunofluorescence, the nucleolus is visible as a 
DAPI-poor rounded region.  
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The nucleolus consists of three main components, identified by electronic microscopy:  
 the fibrillar center (FC) of clustered rDNA (NOR); 
 the dense fibrillar component, consisting of pre-rRNA;  
 the granular component, consisting of nucleolar proteins and pre-ribosomes, derived from rDNA 
transcription in pre-rRNAs, properly rearranged and assembled with ribosomal proteins to move into the 
cytoplasm [Carmo-Fonseca 2000; Schwarzacher 1983].  
 
According to the so-called “plurifunctional nucleolus hypothesis”, this compartment plays an important role 
not only in ribosome biogenesis, but also in cellular stress response, cell cycle regulation [Visintin 2000] and 
cell growth [Zhang 2010], cell aging, post-translational modifications (phosphorylation and sumoylation) of 
proteins and retention/sequestration of molecules normally active outside the nucleolus.  
Moreover, nucleolar activity is linked with several pathologies. As an example, B2310 nucleolar protein and 
nucleolin, two major nucleolar components, are implicated in cancer pathogenesis and cell proliferation, as 
indicated by the findings of: i) high nucelolin levels in tumours and actively dividing cells and ii) nucleolin 
need for chromosome congression and maintenance of mitotic spindle integrity [Ugrinova 2007]. 
Furthermore, nucleostemin is able to interact with p53/Mdm2 pathway, with a potential role in cell 
transformation, and some viruses interact with the nucleolus with recruitment of nucelolar proteins 
facilitating virus replication [Pederson 2011; Sirri 2008; Amin 2008] 
 
Perinucleolar Compartment (PNC)  
PNC is a discoid structure, situated on the nucleolus, covering a portion of its surface as a “cap”. PNC is not 
detectable in all cell types, but it is specific for mammalian transformed cell lines and tumour derived cell 
lines or tumour biopsy, suggesting a role in tumour initiation or progression. The perinuclear compartment 
was originally described during the characterization of hnRNP I /PTB11 protein, which localizes in the 
perinuclear area: the PNC is physically associated with the nucleolus but constitutes a distinct and dynamic 
structure, moving discretely along the nucleolar periphery. As it happens with nucleoli, PNC is disassembled 
during mitosis and reconstituted during late telophase. PNC is characterized by enrichment in specific 
proteins (mainly involved in processing pol II-derived RNAs) and RNAs, especially small non coding RNAs 
transcribed by pol III (which though are not transcribed in PNC). Among perinucleolar proteins, PTB is 
involved in pre-mRNA splicing, alternative splicing and regulation of RNA polyadenilation and translation: in 
general, the enrichment of RNA processing proteins in the PNC suggests a role in RNA metabolism. Some of 
PNC-associated proteins are known to interact with one another [Pollock and Huang 2010]. 
                                                          
10 Also known as nucleophosmin (NPM) 
11 Polypirimidine Tract Binding 
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The integrity and stability of PNC is strictly dependent on RNAs: RNAse, but not DNAse, treatment on 
permeabilized cells, disrupts perinucleolar compartment. Similarly specific inhibition of RNA pol II activity 
can determine PNC disassembly. 
 
BOX 2 - CENTROSOME, NUCLEUS AND NUCELOLUS: THE TRICKY TRIO 
Immediately after centriole discovery, the existence of a nucleus-centrosome axis has been postulated. NC-
axis is oriented and paired with the polarization and migration axis of many cells types (such as neurons 
and fibroblasts), raising the hypothesis of a role for centrosome and nucleus positioning in the regulation of 
cell polarity and migration [Wakida 2010; Gant Luxton 2011]. Indeed centrosome ablation has been 
demonstrated to inhibit cell polarization. MTs act as major actors in this process, organizing a dynamic 
structure along NC-axis and regulating vesicular trafficking and nuclear movement during cellular migration 
and polarization (fig.6) 
 
Figure 6 Effector functions of the NC-axis (ERC is the perinuclear endocyitic recycling compartment).  
From Gant Luxton 2011 
 
Typically, MTs minus-ends are anchored to the centrosome, and the plus end can extend freely in the 
cytoplasm, but because of nucleus proximity, MTs spreading from centrosome is not symmetrical, and it is 
strictly regulated by nucleus and centrosome position (that means by NC axis). NC axis ensures polarization 
of vesicular compartments (Golgi and exocytic apparata) thanks to interactions with the MTs network and 
with the motor protein dynein: in migrating cells, where nuclear movement is functional to migration, 
dynein plays a key role in keeping closed nucleus and centrosome, as well as myosin II. Very interestingly, 
Par6α localizes to the centrosome and is essential for centrosome positioning during glial-guided neuronal 
migration. 
Cdc42, already identified as MARK4 potential interactor (see before), is implied in controlling NC-axis 
formation during fibroblasts migration, thanks to its effect on Par6 and MRCK12. 
Also actin and myosin II are implied in defining the NC axis, together with cell-cell junctions mediated by 
cadherin. Similarly, these effectors and processes can be crucial during cell division [Gant Luxton 2011]. 
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Very interestingly, nucleus-centrosome interactions extend also to the nucleolus. Representing the most 
active and dynamic nuclear domain, the nucleolus plays a prominent role in various cellular processes, such 
as cell proliferation, cell-cycle regulation and various aspects of ribosome biogenesis. It has been 
demonstrated that depletion by siRNA of nucleolar major components, such as B23 and nucleolin, results in 
cell growth arrest, delays in mitotic entry and increase in apoptosis, together with accumulation of 
micronuclei and multiple nuclei or, more generally, aberrant nuclear morphology, and rearrangements at 
severe nucleolar components. In addition, after nucleolin silencing, a significant number of mitotic cells 
showed defects in centrosome duplication, with multiple centrosomes and multipolar spindles, sustaining 
the importance of nucleolar proteins for centrosome duplication [Ugrinova 2007, Amin 2008]. 
 
2.5 CONCLUSION 
MARK4, by phosphorylating MAP proteins, regulates microtubule dynamics and influences the 
multiple cellular processes implying microtubules [Brajenovic 2004, Matenia 2009]. 
Additional hints about MARK4 regulation in microtubules dynamics, particularly those affecting 
the centrosome and the midbody, stemmed from the evidence that both MARK4 isoforms localize 
in these cellular compartments, taking part in all phases of cell cycle [Magnani 2009]. 
MARK4L association with the nucleolus in glial tumours [Magnani 2009], like others protein 
kinases sequestered in this compartment, could underlie a spatial regulation of the kinase by 
alternate translocation in and out of the nucleolus, according to cell cycle phases [Visintin and 
Amon, 2000]. 
MARK4 implication in cell proliferation, pinpointed by cytogenomics and by molecular and 
expression profiles, features in the dual nature of the two different isoforms (MARK4L and S) the 
potential target of dysregulation in glial tumours. 
Interestingly, MARK4L, the alternative splicing variant, has been found up-regulated in glioma. 
Alternative mRNA splicing has been considered a mechanism not only increasing proteomic 
complexity but also implied in cancer, through its involvement in the activation/inactivation of 
oncogenes and tumour suppressor genes and through the generation of chromosomal instability 
(CIN) [Lòpes-Saavedra & Herrera, 2010]. CIN is a common feature of aneuploid cancer cells and 
defects in the regulation of centrosome numbers are considered an intriguing mechanism 
underlying aneuploidy [Duesberg 2006; Weaver 2007]. Defects in centrosomal number and 
structure have been well documented in gliomas *D’Assoro 2002; Katsetos 2006; Magnani 2009+, 
raising the issue whether the increased levels of MARK4L, isoform of a gene involved in the 
microtubule dynamics, may concur to errors in chromosomal segregation driving gliomagenesis.  
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3. GLIOMA 
Glioma, the most common type of primary brain tumour in adults, accounts for more than 70% of 
all the tumours in the Central Nervous System (CNS) [Ohgaki 2009], with high incidence in children 
between 0-8 years and in adults between 50-70 years and a slight male predominance [Gladson 
2010].  
 
3.1 HISTOLOGICAL CLASSIFICATION 
Classification of gliomas is based on histological features, that resemble astrocytes, 
oligodendrocytes or ependymal cells. 
The two main cell types identifiable in the human brain are in fact neurons (2-10% of the cells in 
the CNS) and glia, for which three different sub-populations can be distinguished:  
 Astrocytes, the most abundant glial cells, are responsible of neuron nourishing and 
protection, regulation of synapse formation and activation of the immune response 
 Oligodendrocytes release neuronal growth factors and cover neuronal axons with their 
cytoplasmatic processes to form myelin  
 Microglia, mainly located in proximity of blood capillaries cells, act as phagocytes, with a 
protective role.  
 
According to World Health Organization (WHO) classification, gliomas are classified as follows (drafted in 
1993 and updated in 2008) [Rousseau 2008] 
ASTROCYTIC TUMOURS: 
 Pilocytic astrocytoma  
 Diffuse astrocytoma (fibrillary, protoplasmic and gemistocytic astrocytomas) 
 Anaplastic astrocytoma 
 Pilomyxoid astrocytoma 
 Glioblastoma 
 Giant cell glioblastoma 
 Gliosarcoma 
 Pleomorphic xantoastrocytoma 
 Subependymal giant cell astrocytoma 
- OLIGODENDROGLIAL TUMOURS: 
 Oligodendroglioma 
 Anaplastic oligodendroglioma 
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- MIXED GLIOMAS: 
 Oligoastrocytoma 
 Anaplastic oligoastrocytoma 
- EPENDYMOMAS 
- OTHER NEURONAL, NEURO-GLIAL AND NEUROEPITHELIAL TUMOURS 
 
3.2 WHO MALIGNANCY CLASSIFICATION 
Gliomas can be classified in four malignancy grades, depending on the presence/absence of 
nuclear atypia, mitosis, microvascular proliferation and necrosis: 
 
 WHO grade I: lesions with low proliferative potential and with a good prognosis 
(treatment with surgical resection is usually sufficient for the complete recovery). 
 WHO grade II: generally infiltrating lesions with low mitotic activity and possible 
recurrences. Some of these tumours can progress to higher malignancy grade lesions. 
 WHO grade III: lesions with histological evidence of malignancy, generally 
characterized by high mitotic activity, pronounced anaplasia and infiltrative capacity. 
 WHO grade IV: lesions with high mitotic activity, prone to necrosis and generally 
associated with a rapid pre- and post-operation evolution of the disease. 
 
The WHO classification, however, is not sufficient for a correct diagnosis or prediction of survival 
and therapy response: gliomas show in fact considerable heterogeneity and variability among 
tumours of the same type and grade, and within individual tumours, so that biopsies can often not 
be really representative of the whole tumour mass. In addition, genetic alterations can differ in 
tumours of the same histotype: classification on the basis of tumour genetics could thus lead to a 
more accurate prognosis prediction. 
 
3.3 CLINICS 
Symptoms: Depending on the anatomical site, as characteristic of brain tumours, symptoms are 
typically due to increased intracranial pressure: 
 partial or generalized seizures (epilepsy); 
 nausea, vomiting, drowsiness, headache, visual abnormalities, changes 
in speech, hearing or balance.  
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 focal and progressive neurological deficits. The type of deficit (motor or 
sensory) is generally indicative of the tumour site; 
 cognitive dysfunctions, in most cases symptomatic of meningeal 
involvement or diffuse tumour infiltration. 
Diagnosis:   
 Magnetic resonance imaging or computed tomography (although less 
sensitive) to confirm a suspect of brain tumour; 
 Surgical biopsy with histological examination to diagnose tumour type and 
grade. 
Therapy:  Glial tumours are treated by surgery, radiation and chemotherapy. Complete 
resection is difficult because of tumour location and its typical extensive infiltration 
into surrounding normal tissue. However, even though not curative, surgery can 
establish the diagnosis and relieve symptoms by decompressing the brain. To 
increase survival, surgery is usually combined with adjuvant post-operation 
radiotherapy and chemotherapy (temozolomide, nitrosurea or by the combination 
of procarbazine, lomustine and vincristine – PCV), however, disease recurrence is 
virtually inevitable and very common. Both the invasive nature of the tumour and 
its heterogeneity probably contribute to the poor response to currently available 
treatment regimens [Park 2009].  
 
Thanks to advances in understanding the molecular mechanisms of gliomagenesis, 
new therapies are being developed, in order to inhibit transduction pathways often 
constitutively altered and driving uncontrolled proliferation in glial tumours 
[Sathornsumetee 2007]. Monoclonal antibodies and kinase inhibitors unfortunately 
showed little efficacy, probably because of their low specificity and reduced ability 
to cross the blood brain barrier [Chi 2007].  
Recent therapeutic advances include immunotherapy and anti-angiogenic drugs, 
such as anti-VEGF drugs (the Vascular Endothelial Growth Factor is responsible for 
the high vascularization commonly found in gliomas and is involved in a pathway 
frequently altered in these tumours) [Jain 2007].  
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Prognosis:  The median survival depends on tumour grade and is estimated around 5-8 years 
for grade II tumours, 3 years for grade III anaplastic astrocytomas and 12-18 months 
for glioblastomas (with typically a shorter survival for patients > 60 years old) 
[Gladson 2010]. 
 
3.4 AETIOLOGY 
 
Glioma risk factors: 
Specific risk factors for glioma have not yet been identified. In general, occupational exposure to 
organic solvents or pesticides [Gladson 2010], and exposure to ionizing radiations [Fisher 2007] 
can be predisposing. There are hints of association between immunological factors and gliomas, 
with a lower risk for atopic people [Linos 2007] and a correlation between high IgE and a longer 
survival [Wrensch 2006]. Since Cytomegalovirus (CMV) RNA can be detected in glioblastomas, 
CMV infection has also been suggested to play a role in the etiology and progression of some 
gliomas [Mitchell 2008].  
 
Genetics: 
Even though most brain tumours are sporadic, some familiar syndromes, such as Li-Fraumeni 
syndrome (involving p53 gene on chromosome 17p13), neurofibromatosis I (NF1 17q11) and the 
Cowden syndrome (PTEN 10q22-q23), are known to be associated with an increased incidence of 
brain tumours: in these context gliomas occur in combination with other clinical signs, usually 
tumours in other locations.  
Various cytogenetic abnormalities have been identified in sporadic gliomas: deletions and 
duplications of entire chromosomal segments, Loss Of Heterozigosity and gene amplification, 
genetic alterations in oncogenes and tumour suppressor genes. These anomalies cause 
deregulation of pathways involved in cell cycle control, proliferation and cell differentiation. Even 
though the genes found altered in gliomas are not specific of this class of tumours, their 
combination and their particular accumulation inside glial cell are typical of gliomas and correlate 
with neoplastic transformation and tumour progression [Zhu 2002]. 
It has recently been shown that microRNA (miRNA) play a role in gliomagenesis, since they may 
repress control genes or, when down-regulated, do not target oncogenes anymore [Huse 2010].  
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Oligodendroglioma (WHO grade II) and Anaplastic oligodendroglioma (WHO grade III)  
 1p (1p36.22-p36.31) and 19q13.3 LOH [Smith 2000] are positive prognostic predictors, correlating 
with a favorable response to therapy and a longer survival [Collins 2004]. However, the genes of 
these loci specifically involved in glioma initiation and/or growth promotion are not known 
[Gladson 2010].  
 Promoter methylation or 10q chromosome loss cause downregulation of PTEN 13 tumour 
suppressor gene (10q22-q23).  
 PDGFRα 14can be amplified (4q12), leading to uncontrolled cell proliferation.  
 EGF receptor signaling, together with cell-adhesion receptors and proteases, play an important 
role in promoting both a highly proliferative phenotype and an invasive phenotype. Anaplastic 
oligodendrogliomas (grade III) show genetic and epigenetic aberrations of INK4A-ARF and INK4B, 
involved in regulating the G1/S phase transition. 
 
Astrocytomas (WHO grade II)  
 Frequently exhibit amplification of the PDGFRα and/or PDGFRβ and their ligands (PDGF-A, -B, -C 
and –D), suggesting an autocrine or paracrine loop amplifying this signaling pathway [Shapiro 
2002]. 
  Loss of p53by LOH or missense mutations is common and early in neoplastic transformation 
[Reifenberger 1996].  
 
Anaplastic astrocytomas (WHO grade III)  
originating from II grade astrocytomas, usually are characterized by the same genetic alterations, but 
also genes for cell-cycle progression control are involved:  
 loss of the Rb gene,  
 CDK4 amplification,  
 p16/CDKN2A deletion or promoter hypermethylation  
 MDM2 amplification (p53 inhibitor). 
 
Glioblastomas (WHO grade IV)  
are the most aggressive glial tumours, arising de novo (primary GBM, showing mainly an astrocytic 
component) or from pre-existing low-malignancy lesions (secondary glioblastomas) (Fig. 7). A small 
subgroup of grade IV GBM contains areas of oligodendrocytes and is thus indentified as 
oligodendroglioma-derived (GBMO). Primary and secondary GBM are histologically indistinguishable 
                                                          
13 Phosphatase and Tensin homolog 
14 Platelet Derived Growth Factor Receptor 
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but develop through distinct genetic pathways, showing different expression profile and epigenetic 
aberrations and consequently a diverse response to therapy [Ohgaki 2009].  
 In primary glioblastoma proliferation and invasion can be promoted by amplification and/or 
mutation of the EGFR15 gene, which alterations are mutually exclusive with MDM2 
overexpression. No p53 mutations or deletion are known, while LOH of chromosome 10q 
causes deletion of PTEN gene. Mutations and/or deletions in NF116 can be also present in 
sporadic glioblastomas [Huse 2010]. 
 Hypermethylation of MGMT17 promoter occurs in both primary and secondary GBM, 
representing a positive prognostic factor, since associating with a better response to 
temozolomide therapy [Ney 2009].  
 Genome-wide studies identified RTEL118 and TERT19 SNPs associated with increased glioma 
incidence [Shete 2009; Wrensch 2009].  
 Missense mutations in IDH1 and IDH220 , found in a significant number of astrocytomas and 
oligodendrogliomas, are largely absent in primary glioblastomas, suggesting that primary and 
secondary GBM may originate from different progenitor cells [Ohgaki 2009]; multivariate 
analysis also suggests that they are favorable prognostic markers [Huse 2010]. 
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Figure 7: schematic representation of different grade gliomas. 
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3.5 GLIOMAGENESIS 
The cell of origin of glioblastoma was traditionally thought to be the astrocyte, due to some 
staining/morphologic similarities, and the fact that the astrocyte is one of the few cell types 
capable of proliferation in the mature brain. However, the presence of pluripotential neural 
progenitor cells in the subventricular zone of mature brain, and in glioblastoma tumours, 
prompted to raise the hypothesis of a staminal origin of gliomas [Quigley 2007]. The stem cell 
origin could account for the existence of mixed glial tumours, with both astrocytic and 
oligodendrocytic component, together with the high heterogeneity characterizing brain tumours. 
Moreover, the presence of a progenitor compartment in glioma could offer an explanation for the 
resistance to treatment typical of these tumours, as the neoplastic progenitor may continue to 
seed the brain, despite local treatment to the tumour mass [Quigley 2007]. 
Glioma arising from a tumour initiating stem-like cell (named brain tumour stem cell, BTSC) is now 
universally accepted, but the origin of the BTSC cell itself is strongly debated. 
 
The presence of Cancer Stem Cells (CSCs) with various genetic and epigenetic features in glioma 
could indeed explain the cellular heterogeneity and resistance to therapy characteristic of 
malignant glioblastomas [Reya 2001].  
Cancer stem cells were isolated from glioblastoma biopsies for the first time in 2002 [Ignatova 
2002] and were identified as stem-like cells, growing in neurospheres and being able to 
differentiate in neuronal and astroglial cells. More specifically, the term “Brain Tumour Stem Cell” 
refers to multipotent cells, which thus can differentiate into the three neural cell lineages 
(astrocytes, oligodendrocytes and microglia). BTSC can long-term proliferate and self-renew, and 
are capable of giving rise to tumours in vivo [Vescovi 2006].  
Typically, cancer stem cells account for less than 5% of the cells within the tumour mass [Gladson 
2010] and reside in the perivascular area of the tumour (vascular niche), offering a specialized 
microenvironment which allows the maintenance of CSCs features [Huse 2010]. Changes in this 
local microenvironment (niche; growth factors levels; interactions with immune cells) may thus 
play a role in glioma formation [Germano 2010; Park 2009].  
Different surface markers (CD133, BMI1, nestin, Sox2, Notch) have been tested to identify and 
isolate CSCs from GBMs but this sole approach was proven to be insufficient: in fact the genetic 
deregulation that occurs in cancer may lead to ectopic protein expression [Park 2009].  
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Literature data suggest that tumorigenesis can be achieved by two different mechanism:  
 Hierarchical model: one specific CSC population, among the different stem subpopulations 
of the tumour mass is responsible for repopulating the tumour.  
 Stochastic mechanism: different types of cancer stem cells, with different tumorigenic 
ability, are involved in tumour formation, accordingly with the heterogeneity typical of 
glioblastomas.  
 
Brain tumour Stem Cell may thus derive from oncogenic transformation of different cell types: 
 
 Neural stem cells (NSCs): even though self-renewing and with long life-time, stem cells are 
usually quiescent, thus less prone to acquire genomic errors [Park 2009]. However, survival 
of neural stem cells and maintenance of the undifferentiated state are mediated by 
pathways reported to be constitutively activated in gliomas (Notch, EGFR, SHH21, PTEN, 
BMI1) [Purow 2005; Vescovi 2006; Stiles 2008].  
 In the adult central nervous system, NSCs are located in the Sub-Ventricular Zone (SVZ) of 
the forebrain and the dentate gyrus of the hippocampus, where genesis of new neurons is 
strongly documented.  
SVZ represent the NSCs niche with the highest neurogenic rate, characterized by the 
presence of three undifferentiated and highly proliferative cell types: type A, B and C cells 
(Fig. 8). Type B cells express markers of both mature astrocytes (GFAP22) and immature and 
radial glial cells (vimentin and nestin) and are supposed to be relatively quiescent stem 
cells with low proliferation rate, but generating fast-proliferating, transit-amplifying 
progenitor cells (C cells). Type C cells are multipotent and generate neuronal precursors 
(type A cells or neuroblasts), which leave the SVZ and migrate to several brain areas where 
they terminally differentiate [Galli 2003]. Some C cells express oligodendroglial markers 
(Oligo2, NG2) and originate oligodendrocytes [Stiles 2008]. 
While in vivo endogenous NSC seem able to produce almost exclusively neurons, in vitro 
they are able to generate mainly astrocytes but also oligodendrocytes and neurons. This 
evidence highlights the importance of epigenetic signals in the neurogenic niches, where 
glial cells and neurons exert mutual influences [Gritti 2007]. 
                                                          
21 Sonic HedgeHog. 
22 Glial Fibrillary Acidic Protein. 
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Figure 8 [Left]: stem cells (B cells; blue), neural progenitors (C cells; amber) and neuroblasts (A cells; green) in the 
sub-ventricular zone [Stiles 2008]. [Right]: adult rodent brain ventricle (V) and sub-ventricular zone (SVZ). Arrows 
point to some of the proliferating cells in the SVZ that were labeled after intraperitoneal injection of the thymidine 
analogue, 5-bromodeoxyuridine [modified from Galli 2003]. 
 
 Neural progenitors: being more proliferative than stem cells and differentiated cells, these 
cells can easily undergo oncogenic mutations that are fixed during replication. Many of the 
pathways found abnormally activated in gliomas are also sustained in neural progenitor 
cells, since they are necessary for progenitor proliferation and migration. Progenitors can 
migrate as well as tumour cells, even if glioma cells can proliferate and migrate at the same 
time, whereas progenitor cells have limited migration capacities and enter mitosis only 
after they have reached the final destination [Canoll 2008].  
Neural progenitors are characterized by a high plasticity, and can modify their 
differentiation state in response to specific stimuli [Vescovi 2006].  
 
 De-differentiated mature glial cells: these cells, after mutation accumulation could acquire 
a stem-like phenotype, originating multipotent malignant cells able to sustain glioma 
proliferation. In fact glioma cells express both undifferentiated and differentiated markers: 
a high number of de-differentiation markers, paired with a decrease of differentiation 
markers, correlates with glioma progression [Germano 2010]. However, there is no 
knowledge of a de-differentiation process in these cells capable to originate multipotent 
malignant cells.  
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A new classification of primary glioblastoma has been proposed, on the basis of spatial 
relationship with SVZ (known to be enriched in stem cells) and cortex [Lim 2007]:  
 
 group I: GBM contacting SVZ and infiltrating cortex; characterized by multifocality and tumour 
recurrences noncontiguous with the initial lesion (so with a more invasive and migratory 
phenotype); 
 group II: GBM contacting SVZ but not involving cortex;  
 group III: GBM not contacting SVZ but involving cortex; 
 group IV: GBM neither contacting SVZ nor infiltrating cortex, never multifocal with recurrent 
lesions always bordering the primary site 
 
It has been suggested that group I GBMs originate from transformed NSC, maintaining expression 
of matrix metalloproteinases (as typical of highly aggressive and infiltrating tumours); the contact 
with the SVZ niche, may also be permissive for tumour growth and migration. In contrast, group IV 
GBMs may arise from white matter glial progenitors, which have very limited migration potential.  
 
Worth to be noted, oncogenic transformation and gliomagenesis can be obtained by induction of 
PDGFB expression, in nestin+ progenitor cells, committed oligodendroglial precursors or mature 
GFAP+ astrocytes [Huse 2010] and stimulation of PDGFR signaling can induce tumour-like 
proliferation of NSC. In addition, combinations of oncogenes/ tumour suppressor genes 
deregulation trigger tumorigenesis from differentiated astrocytes [Zhu 2009; Park 2009]. The 
discrepancies in these studies indicate that several different cell types probably harbor 
tumorigenic potential and that their ability to initiate neoplasia may depend on the precise 
mechanisms governing the underlying oncogenic stimulus and/or the molecular subclass of the 
tumour in question [Huse 2010]. 
Experimental models indicate that gliomas can arise from both undifferentiated multipotent cells 
and well differentiated astrocytes: it may be possible that the differences between the primary/de 
novo and secondary/progressive GBM reflect a different cell of origin. 
Certainly, various evidences underline that gliomas could be maintained by a population of 
malignant cells that exhibit stem-like properties of self-renewal and multipotency, irrespective of 
the cell of origin: a stem cell, a progenitor, or a differentiated somatic cell that has reacquired the 
stem-like properties, as summarized in figure 9 [Park 2009, Huse 2010].  
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Figure 9 Although the precise cells of origin for diffuse glioma variants remain 
largely unknown, a selection of likely candidates for each (dashed arrows) is 
indicated. (Modified from Huse 2010) 
 
 
4. RNAi 
RNA interference process (RNAi), identified in C. Elegans [Fire, 1998], consists in the degradation 
of specific mRNA mediated by a homologous double strand: it is a conserved biologic mechanism 
in various eukaryotic organisms, responsible for viral RNA degradation and transposon 
suppression and implicated in regulatory process during embryogenesis [Bernstein 2001]. 
 
A common mechanism has been identified [Elbashir 2001; Dykxhoorn 2003; Bantounas 2004]: 
1. RNAi is triggered by a dsRNA (exogen or viral RNA, transposons, endogenous dsRNA): dsRNA is 
processed by Dicer enzyme and becomes a small interfering RNA (siRNA) 21-22 bp long. 
siRNAs are characterized by a protruding 3’ –OH, as typical of degradation mediated by RNAsi 
III, and a phosphate group at 5’.  
2. The mRNA is silenced by a sequence specific target mechanism: Dicer efficiency is 
proportional to dsRNA length: the longest the dsRNA is, the most are the derived siRNAs and 
the silencing effect. siRNAs derived from Dicer processing are recruited by RISC endonuclease 
(RNA induced silencing complex). 
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3. Target degradation requires evolutionary conserved enzymatic complexes: RISC, by its ATP 
dependent - helicase activity, separates the 2 strands of siRNAs, retaining the anti-sense 
strand [Martinez 2002; Hammond 2000]. The target mRNA is recognized thanks to base-
pairing and digested by RISC [Elbashir 2001]. (Figure 9) 
4.  
 
Figure 9: RNA interference: long dsRNA are processed by Dicer in siRNAs, which are incroporated by 
RISC (Nature reviews Mol Cell Biol 2003, 4: 457-467) 
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RNAi by long dsRNA has been demonstrated to be a very useful tool in functional studies in 
Drosophila and other eukaryotic organisms: unfortunately, in mammals, this approach can only 
generate an unspecific response, mediated by interferon, with inhibition of protein synthesis and a 
global RNA degradation [Bass 2001]. However, RNAi can be induced in mammalian cell lines by 
transfection with chemically syntethized dsRNA 21-22 bp long, that are presumed to directly 
interact with RISC [Elbashir 2001]. 
To obtain a specific silencing, the siRNA molecule has to be designed using specific algorithms 
which identify the best region for silencing in the mRNA target: usually more than one siRNA is 
tested to verify the silencing efficiency [Holen 2002]. 
Secondary structures of siRNA and of the target mRNA can also influence the silencing efficiency, 
together with the transfection method (electroporation, lipid-based transfection). 
Even though siRNAs represent a very useful tool in functional studies, the main bias is represented 
by their transient activity: cellular duplication causes a progressive dilution of the siRNA 
molecules, until a level under the threshold necessary to maintain the silencing: thus in actively 
replicating cells, silencing duration is strongly correlated with the number of cell divisions. 
[Elbashir 2001]. Usually, the effect on the cell phenotype persists for a maximum of 7 days, 
sometimes not sufficient to obtain the silencing of a gene codifying for long half-life proteins 
[Paddison 2002]. 
Literature reports depletion of centrosomal proteins (such as Tastin, Cep55, Centriolin and 4.1R) 
by siRNA [Yang, 2008; Fabbro 2005; Gromley 2003; Krauss 2008], resulting in severe alteration of 
cell cycle progression and apoptosis induction, multi-nucleated cells, mitotic arrest and alterations 
in spindle formation, compatible with the disruption of centrosome functions. 
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1. CELL CULTURES 
1.1 Human primary glioma cell lines 
Glioblastoma (GBM) cell lines used for functional studies have been selected from a panel of 21 human 
primary glioma cell lines obtained from post-surgery specimens and characterized as described elsewhere 
[Perego 1994; Beghini 2003; Magnani 2004; Roversi 2006]. Features of cell lines are reported in table 1. 
 
 
Table 1: clinic and pathological features of GBM derived cell lines.. 
 
Cells were grown in RPMI23 supplemented with 5% fetal bovine serum (FBS), 100 U/ml penicillin (Pen) and 
100 U/ml streptomycin (Strep) at 37°C and 5% CO2. They were split during the exponential growth phase 
using trypsin-EDTA24. Cells were tested by Immunofluorescence with DAPI25 to verify the absence of 
mycoplasma contamination. 
MI60 GBM cell line, initially used for RNAi optimization, because showing heterogeneous populations, has 
been replaced with G32 GBM cell line, used in siRNA experiments 
 
1.2 Human normal fibroblasts 
Adult fibroblasts, used as control, were grown at 37°C in a 5% CO2 atmosphere in RPMI supplemented with 
10% FBS and 100 U/ml Pen-Strept. Fibroblasts, derived from skin biopsy, were obtained from “Cell Line and 
DNA Biobank from Patients Affected by Genetic Diseases” (G. Gaslini Institute) - Telethon Genetic Biobank 
Network – Project N. GTB07001 
 
2. PROTEIN HALF-LIFE ASSAY 
In order to better define the duration of RNAi experiments, we performed time-lapse Cycloheximide (CHX) 
treatment (50μg/μL stock solution in 70% EtOH) on MI-60 GBM cell line, harvesting cells at 48, 96, and 120 
hours after CHX addition (final concentration 100μg/μL). Western Blot (WB) (described in paragraph 6 of 
                                                          
23 Developed by Moore at the Royal Park Memorial Institute. 
24 Ethylenediaminetetraacetic acid. 
25 4’,6-Di Amidino-2-Phenyl Indole. 
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this section) was performed to assess the presence of MARK4 protein. Cycloheximide (CHX) is an inhibitor 
of protein biosynthesis in eukaryotic organisms, produced by the bacterium Streptomyces griseus. CHX 
exerts its effect by interfering with the translocation step in protein synthesis (movement of two tRNA 
molecules and mRNA in relation to the ribosome) thus blocking translational elongation. CHX is widely used 
in biomedical research to inhibit protein synthesis in eukaryotic cells studied in vitro. It works rapidly and its 
effects are rapidly reversed by simply removing it from the culture medium.  
 
3. RNAi 
MARK4L and MARK4S knockdown was obtained by RNAi, which relevant features are summarized in BOX 1. 
BOX 1 – RNAi 
RNA interference (RNAi) is one of the most important technological breakthroughs in modern biology, considered 
essential for studying gene function, allowing to directly observe the effects of the loss of function of specific 
genes in mammalian systems. It has become a prominent tool for protein knockdown studies, phenotype analysis, 
function recovery, pathway analysis, in vivo knockdown, and drug target discovery.  
The molecules that mediate RNAi are short dsRNA oligonucleotides, 21 nucleotides in length, internally processed 
by Dicer enzyme: the cleavage products are short interfering RNA (siRNA).  
RNAi technology takes advantage of the cell natural machinery to effectively knockdown expression of a gene with 
transfected siRNA. There are several ways to induce RNAi: synthetic molecules, RNAi vectors, and in vitro dicing.  
In mammalian cells, siRNAs specifically degrade the target mRNA: the antisense strand of siRNA associates with 
the multiprotein complex, or RNA-induced silencing complex (RISC), which then identifies and cleaves at a specific 
site the corresponding mRNA, next targeted for degradation. Ultimately this process results in the loss of protein 
expression.  
 
We performed RNAi by Silencer® Select siRNAs or Stealth RNAi™ siRNA duplexes, obtained by Ambion and 
Invitrogen, transfected by lipid-mediated transfection with LipofectamineTM RNAiMAX (Invitrogen). This 
transfection reagent is a cationic lipid formulation suitable for delivering molecules across a diverse range 
of commonly used cell lines and specifically developed for highly efficient delivery of Stealth RNAi™ siRNA 
or Silencer® Select siRNA to mammalian cells. 
It has been reported that it can cause cytotoxicity, thus determining an apparent off-target effects due to 
suboptimal or excess in delivery reagent. One cause of off-target effects is the up- or down-regulation of 
genes due to the siRNA delivery procedure. Off-target effects can also be due to non-specific knockdown 
mediated by the siRNA duplex itself.  
To avoid these problems, different concentrations of siRNA were tested to determine the most favorable 
conditions, that is the lowest siRNA concentration that gives the desired level of knockdown in RNAi 
experiments.  
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3.1 Assessing of transfection efficiency 
To verify the effective internalization of dsRNA used in RNAi experiments, GBM cell lines and fibroblasts 
were tested using Cy3-Luciferase siRNA (Upstate), easily detectable by fluorescence microscopy: 
internalization was considered optimal when at least 90% of the treated cells showed cytoplasmic 
fluorescent signal at different observation time (24 and 48 hours after transfection). Transfection of Cy3-
Luciferase siRNA has been performed using both reverse and forward transfection protocol, as described 
further on. 
 
3.2 Negative Control 
siRNA negative control, not targeting any specific gene product (because designed to have no similarity to 
mouse, rat, or human transcript sequences), was tested in both GBM cell lines and fibroblasts under study. 
Since we found that the Silence Negative control siRNA at 40nM (siRNA#1 Ambion) did not show significant 
impact on cell proliferation, apoptosis or cell morphology, we used it to distinguish non specific (NS) effects 
on siRNA treated cells.  
 
3.3 Silencer siRNAs and Stealth siRNAs 
To obtain MARK4 knockdown we used different siRNA, selected after testing their efficiency (Table 2): 
siRNA used in the knockdown experiments are indicated with (*).  
siRNA  sense antisense 
target 
region 
(*) siRNA anti MARK4S+L # 1089 (Ambion) GGUUGCCAUCAAGAUUAUCtt GAUAAUCUUGAUGGCAACCtc ex 2-3 
  siRNA anti MARK4S+L # 1090 (Ambion) GGGAAACUGAGGAAAUCUUtt AAGAUUUCCUCAGUUUCCCtc ex 18 
(*) Stealth siRNA MARK4S #10 (Invitrogen) CGAUCCCUCUAAACGGCAGAACUCU AGAGUUCUGCCGUUUAGAGGGAUCG ex 16 
  Stealth siRNA MARK4S #11 (Invitrogen) GAUCCCUCUAAACGGCAGAACUCUA UAGAGUUCUGCCGUUUAGAGGGAUC ex 16 
  Stealth siRNA MARK4S #17 (Invitrogen) UCUAAACGGCAGAACUCUAACCGCU AGCGGUUAGAGUUCUGCCGUUUAGA ex 16 
Table 2: siRNA used in MARK4 silencing experiments 
 
siRNAs silencing both MARK4S and MARK4L were Silencer Validated siRNAsTM (Ambion # 1089 and # 1090) 
which are siRNA duplexes already verified to reduce the expression of their individual target genes. Each 
one has also been functionally proven and is guaranteed to reduce target gene expression at least 70% 
after 48 hours post-transfection. 
Stealth RNAi™ double-stranded are blunt-ended 25-mers that reduce significantly off-target effects, avoid 
induction of stress response pathways, and with enhanced nuclease stability without loss in potency. 
Stealth siRNATM used in knockdown experiments are customized siRNA, designed by BLOCk-iTTM RNAi 
Designer (Invitrogen – Free Use on line) to specifically target exon 16, skipped in MARK4L isoform, and thus 
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able to determine specific MARK4S silencing. The 3 Stealth siRNA molecules obtained with the design 
software were all tested for efficiency in MARK4S knockdown.  
 
Based on MARK4 half-life assay, we performed experiments with the following time table: 
Day 0:  Reverse Transfection 
Day 2:  Forward Transfection 
Day 3:  72 hours silencing data collection 
Day 5:  120 hours silencing data collection 
For cell curve and cell cycle analysis by cytofluorimeter (see section 8 of this paragraph), cells were 
collected every 24 hours since silencing initiation. 
 
3.4 Reverse transfection 
In reverse protocol, transfection mix is prepared and then dispensed in each plate: only after, cells and 
medium are added, following concentration ranges given by the manufacturer (Table 3).  
 
cell number
cell 
suspension
Ø 35 mm 500 uL 100.000-150.000 2 mL
Ø 60 mm 1 mL 200.000-300.000 4 mL
Ø 100 mm 2 mL 400.000-600.000 8 mL
transfection 
mix volume
plate
reverse transfection forward transfection
culture medium
2 mL
4 mL
8 mL  
Table 3: volume/cells number correspondence for reverse and forward transfection protocol in culture plates 
 
RNAi duplexes–Lipofectamine® RNAiMAX complexes were prepared as follows: RNAi duplexes were added 
to RPMI Medium without serum and without antibiotics to achieve the optimal final concentration. After 
gentle mixing, Lipofectamine® RNAiMAX was added to the mix (1uL in 100 μL mix), then incubated for 10-
20 min at RT and subsequently dispensed in each plate. Cells, diluted in RPMI with 5-10% FBS without 
antibiotics were added to each plate, then incubated at 37°C 5%CO2 until ready to assay for gene 
knockdown or to prolong transfection by forward transfection protocol. 
 
3.5 Forward transfection 
In forward transfection, the mix is generally prepared and added the day after the plating of cells. We used 
this procedure when we need to repeat the transfection 48h hours after the reverse transfection, in order 
to maintain the silencing over than 120 hours. 
The transfection mix was prepared and incubated as previously described for reverse protocol. 
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The same plates used for reverse transfection, were treated as follows: 
culture medium was removed and the correspondent amount of transfection mix (Table 4) was added to 
each plate. RPMI with 5-10% FBS without antibiotics was added to each plate, then incubated at 37°C 
5%CO2 until ready to assay for gene knockdown. 
 
3.6 Transfection optimization 
Different concentrations and combinations (to verify a possible cooperative interaction in silencing) of each 
siRNA were tested in order to define the optimal transfection condition (Table 4): knock down efficiency 
has been evaluated by Real Time RT-PCR.  
 
siRNA 
combination 
siRNA 1 
Final  
Concentration (nM) 
siRNA 2 
Final 
Concentration (nM) 
1 anti MARK4S+L # 1089 24 - - 
2 anti MARK4S+L # 1089 40 - - 
3 anti MARK4S+L # 1089 60 - - 
4 anti MARK4S+L # 1089 70 - - 
5 anti MARK4S+L # 1089 80 - - 
6 anti MARK4S+L # 1090 24 - - 
7 anti MARK4S+L # 1090 40 - - 
8 anti MARK4S+L # 1090 60 - - 
9 anti MARK4S+L # 1089 40 anti MARK4S+L # 1090 40 
10 anti MARK4S+L # 1089 40 anti MARK4S+L # 1090 20 
11 anti MARK4S+L # 1089 30 anti MARK4S+L # 1090 30 
12 Stealth anti MARK4S #10 60 - - 
13 Stealth anti MARK4S #10 80 - - 
14 Stealth anti MARK4S #11 60 - - 
15 Stealth anti MARK4S #11 80 - - 
16 Stealth anti MARK4S #17 60 - - 
17 Stealth anti MARK4S #17 80 - - 
18 Stealth anti MARK4S #10 30 Stealth anti MARK4S #17 30 
19 Stealth anti MARK4S #10 30 Stealth anti MARK4S #11 30 
20 Stealth anti MARK4S #11 30 Stealth anti MARK4S #17 30 
Table 4: siRNA combinations tested to optimize MARK4 silencing 
 
4. RNA AND PROTEIN EXTRACTION 
4.1 RNA extraction  
Adherent cells were treated with 1 mL of TRIreagent (Total RNA Isolation reagent, Sigma), to preserve 
nucleic acids and dissolve cellular components.  
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As instructed by the manufacturer, the solution was supplemented with chloroform, and after 15’’ vigorous 
shaking, was centrifuged at 14,000 rpm for 15 min at 4°C, obtaining three distinct phases: an upper-
aqueous phase (containing RNA), an interphase (containing DNA), and lower-organic phase (containing 
proteins). RNA has been subsequently obtained by precipitation: 500 μL of isopropyl alcohol were added to 
the sample and incubated 15’ at RT; after centrifugation at 14,000 rpm 15’ at 4°C, RNA has been isolated 
and resuspended in DEPC water. DNase I (RNase-free, New England Bio-Labs, Inc., Ipswich, MA, USA) 
treatment has been performed on RNA samples to remove residual DNA, following manufacturer’s 
protocol. 
RNA quantity and quality were determined by measuring absorbance at 230, 260 and 280 nm with the ND-
1000 Spectrophotometer (NanoDrop products, Waltham, MA, USA, by Thermo Fisher Scientific, Inc.). 
 
4.2 Protein extraction  
After harvesting and washing in PBS, cells were counted, resuspended in lysis buffer (100 µl /1,000,000), 
and incubated on ice for 30 min with occasional inversion to ensure complete lysis.  
After incubation, the lysates were centrifuged at 16,000 g for 25 min (at 4°C to prevent protein 
degradation): the supernatant (whole cell lysate) was stored at -20°C/-80°C.  
Protein concentration was determined using the BCA Protein Assay Kit (Pierce, Rockford, IL, USA), according 
to the manufacturer’s protocol, using ND-1000 Spectrophotometer. 
 
Lysis buffer: 150 mM NaCl, 50 mM Tris pH 7.5, 1% NP-40, 0.25% deoxycholic acid, 
protease inhibitor cocktail (Complete EDTA-free - Roche). 
 
5. GENE EXPRESSION ANALYSIS 
To verify the effective knockdown of MARK4 S and L mRNAs, Real-time quantitative PCR was carried on 
cDNAs derived from transfection experiments.  
 
5.1 Reverse transcription PCR (RT-PCR)  
Reverse transcriptase PCR (RT-PCR) allows transcribing mRNA into its complementary DNA (cDNA) by 
reverse transcriptase enzyme.  
600 ng of RNA extracted from cells treated with siRNA, were retro-transcribed by High capacity cDNA 
reverse transcription kit (Applied Biosystems), with random examers, according to the manufacturer’s 
instructions. Two independent reactions were carried on and a PCR amplifying the housekeeping gene 
GAPDH was performed in order to verify the efficiency of retrotranscription. 
   forward primer:   5’-ACAACAGCCTCAAGATCATCAG-3’; 
 reverse primer:   5’-GGTCCACCACTGACACGTTG-3’; 
 annealing temperature:  62°C. 
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5.2 Real-time quantitative PCR  
Real-time PCR is a highly sensitive, specific and reproducible technique which measures the expression of 
the target gene combining a traditional Polymerase Chain Reaction with a TaqMan probe, complementary 
to the inner region of the PCR product, emitting fluorescence when the template is amplified: TaqMan 
probe is an oligonucleotide with a reporter fluorophore on the 5’ end and a quencher dye on the 3’ end. 
During PCR elongation the DNA polymerase breaks the probe so that the reporter fluorophore is no longer 
switched off by the quencher and the emitted fluorescence is recorded. Detected fluorescence is therefore 
proportional to the accumulation of PCR products.  
Amplification data are collected during the PCR exponential phase (when PCR products are directly 
proportional to the original quantity of the target gene cDNA), and expressed as CT (Threshold cycle) value, 
corresponding to the PCR cycle at which PCR products are firstly generated. During data analysis, 
normalization is necessary for relative quantification, and control genes, which are constitutively expressed 
endogenous genes (housekeeping genes), have to be analyzed in parallel for this purpose. 
 
5.2.1 TaqMan assays and Real-time PCR 
Real-time PCR was performed with Applied Biosystems TaqMan Fast Universal PCR Master Mix 2x No 
AmpErase UNG (consisting of DNA polymerase, buffer and dNTPs) and TaqMan Gene Expression Assays 
(specific for each target or control gene), which features are reported in Table 5. Mix conditions are 
reported in Table 6. 
ASSAY PRIMER SEQUENCE PROBE SEQUENCE 
MARK4L 
F 5’ CCGAAGGGTCGCAGACGAA 3’ 
5’ CCTGAGGTCACAAGTT 3’ 
R 5’ CCGTTTGATCCCAAGGTAGATG 3’ 
MARK4S 
F 5’ GTTACCCTCGATCCCTCTAAACG 3’ 
5’ CAGAACTCTAACCGCTGTGT 3’ 
R 5’ GTTCGTCTGCGACCTGATCTT 3’ 
ACTIN β Inventoried assay reagent; ID: Hs99999903_m1 
GAPDH Pre-developed assay reagent; ID:4333764F 
RPLP026 Pre-developed assay reagent; ID:4333761F 
 
Table 5: primer and probe sequences for MARK4S and L Assays on demand; ID for control gene assays.  
 
H20 2.5 µL  
Master Mix (2x) 5.0 µL  
TaqMan Assay (20x) 0.5 µL  
cDNA (1.5 fold dilution) 2 µL  
Table 6: Real Time RT-PCR mix 
                                                          
26 Ribosomal Phosphoprotein Large P0. 
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MARK4 primers and probes were designed on the boundary between exons, to avoid genomic DNA 
amplification and in order to have assays specific for each isoform: MARK4S forward primer and probe bind 
exon 16, absent in MARK4L mRNA, and reverse primer is on the boundary between exons 16 and 17; 
MARK4L forward primer was placed between exon 15 and 17 (joined by alternative splicing in MARK4L 
mRNA), while the probe and reverse primer bind exon 18. 
Reactions were performed on the StepOne Real-Time PCR System (Applied BioSystems), under 
these conditions:  
95°C 95°C
20’’ 3’’
60°C
20’’
40 cycles
 
All samples were retro-transcribed in two independent reactions and loaded in triplicate in Real-Time 
experiments.  
 
5.2.2 Relative quantification analysis 
CT data were analyzed by StepOne Software (v1.2; Applied Biosystems) or, alternatively using two different 
methods: the 2-ΔΔCT method (also known as Livak method, [Livak 2001], for which, being more 
homogeneous, a single control gene was sufficient) and the geNorm method (E-ΔCT) [Vandesompele 2002] 
(used for assay validation and described further on).  
In both cases, MARK4S and L (target genes) expression levels were normalized by control genes and then 
referred to a reference sample (Non-Specific - NS), whose expression level was set as 1. 
 
Livak method: for each sample the target gene expression level = 2-ΔΔCT  
   
  where: ΔΔCT = sample ΔCT – reference ΔCT; 
   sample ΔCT = [target gene CT – control gene CT] in the sample; 
   reference ΔCT = [target gene CT – control gene CT] in the reference; 
   (sample and reference ΔCT correspond to the mean value between  
   the ΔCTs of the two independent RT reactions). 
 
geNorm method: this method uses multiple control genes and the amplification efficiency (E, set as 2 in the 
2-ΔΔCT method) is calculated for each assay, taking into account the different efficiency of each assay.  
Briefly: 
1) For each assay, serial dilutions of a pool of cDNAs are processed by Real-time PCR and CT values are 
put in a graph with the respective logarithmic dilution values. The amplification efficiency E 
corresponds to 10-1/S, where S is the slope of the interpolation line. 
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2) For each assay, the relative quantity (Q) is calculated: Q = E-ΔCT 
  where ΔCT = sample CT – reference CT. 
3) For each sample, normalization factor (NF) is set on the basis of the geometrical mean (GM) of the 
relative quantities (Qs) of control genes: 
  NF = GM of control gene Qs for each sample / GM of all the GMs.  
4) For each sample, the target gene relative quantity = Q / NF is calculated. 
 
The target gene mRNA relative quantification corresponds to the mean value between the two 
independent RT reactions.  
Real-time expression data were expressed as mean ± standard error, useful to identify statistically 
significant data. 
 
5.2.3 TaqMan assay validation 
Before performing the relative quantification analysis on the samples under study, we evaluated 
amplification efficiency and stability of all the assays (MARK4S, MARK4L, actin β, GAPDH, HPRT, RPLP0).  
 
Assay amplification efficiency 
For each assay, we performed Real-time PCR on serial dilutions of a pool of glioma cDNAs. The obtained CT 
values were graphed with the respective logarithmic dilution values. Amplification efficiency (E) was 
calculated as E=10-1/S, where S is the slope of the interpolating line, and was near 2 for all the assays (table 
8): E-value equal to 2 correspond to a 100% amplification efficiency, meaning that ideally PCR product 
quantity should double at every cycle. Therefore all the tested assays proved to have a very good 
amplification efficiency.  
 
Assay stability 
Assay stability is the ability to amplify the target gene with the same efficiency in a broad range of sample 
dilutions.  
To assess this parameter, we first calculated the relative quantity (Q) of each gene in the cDNA serial 
dilutions, according to the following formula: Q=E-ΔCT (ΔCT =sample CT – reference
27 CT) and then used the 
GeNorm software (version 3.5; http://medgen.ugent.be/jvdesomp/genorm/) to sort the assays on the basis 
of their stability (table 7). We therefore decided to use GAPDH and RPLPO as control genes, since they were 
the most stable ones in the tested samples: RPLP0 has been used as reference instead of β Actin because 
the latter demonstrated to be less stable after MARK4 silencing. 
                                                          
27 In this case the reference was the less diluted sample. 
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ASSAY DILUTIONS CT S  E  ΔCt RELATIVE QUANTITY STABILITY 
GAPDH 
1 16.52 -3.30 2.01 0.00 1.00  
more stable 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
less stable 
1:10 19.73   3.21 0.11 
1.100 23.05   6.52 0.01 
1:1000 26.41   9.89 0.00 
ACTB 
1 16.78 -3.65 1.88 0.00 1.00 
1:10 20.35   3.57 0.11 
1.100 24.02   7.25 0.01 
1:1000 27.71   10.93 0.00 
 
 
RPLP0 
1 17.74 -3.28 2.02 0.00 1.00 
1:10 20.85   3.10 0.11 
1.100 24.18   6.44 0.01 
1:1000 27.56   9.82 0.00 
HPRT 
1 21.78 -3.31 2.00 0.00 1.00 
1:10 24.95   3.18 0.11 
1.100 28.20   6.43 0.01 
1:1000 31.74   9.96 0.00 
MARK4L 
1 23.75 -3.40 1.97 0.00 1.00 
1:10 27.00   3.25 0.11 
1.100 30.50   6.75 0.01 
1:1000 33.92   10.17 0.00 
MARK4S 
1 28.00 -3.54 1.92 0.00 1.00 
1:10 31.26   3.25 0.11 
1.100 35.00   6.99 0.01 
1:1000 N.D.   / / 
 
Table 7: assay amplification efficiency (E) and stability. For each assay, CT values (3
rd
 column), corresponding to serial 
dilutions of a pool of glioma cDNAs (2
nd
 column), are displayed. S=slope of the interpolating line. N.D.=undetermined. 
 
6. WESTERN BLOTTING 
Equal amounts of the whole cell extracts (usually 15-25 µg) were supplemented with reducing SDS28 loading 
buffer (Blue loading buffer pack, Cell Signaling Technology, Inc., Beverly, MA, USA) and denatured at 99°C 
for 3 min.  
Proteins were separated by 4% (Stacking; 100V for 10’) and 10% (resolving; 130V for 115-120’) SDS 
PolyAcrylamide Gel Electrophoresis (SDS-PAGE) and then transferred by electroblotting to a PVDF29 
membrane (Roche). Mini-PROTEAN Tetra cell and Trans-blot semi-dry electrophoretic transfer cell (both 
Bio-Rad) were respectively used for electrophoresis and electroblotting (10V, 30 min) as instructed by the 
manufacturer. Biotinylated protein ladder (Cell Signaling Technology) and ColorBurst electrophoresis marker 
(Sigma) were used as MW-standards.  
                                                          
28 Sodium Dodecyl Sulphate. 
29 Polyvinylidene fluoride. 
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Membranes were then washed twice (10 min each) in PBS-T (PBS – 0.3% Tween20) and blocked with 5% 
skimmed milk in PBS-T for 1 or 2 hours (for MARK4S and L respectively) at Room Temperature (RT), in 
agitation. 
For relative quantification studies, the membranes were cut horizontally immediately after the blocking 
step and incubated with the appropriate antibodies. 
The membranes were incubated with primary antibodies (in PBS-T) at 4°C overnight in agitation, washed 4 
times in PBS-T and then incubated at RT for 1.5 hours, in agitation, with secondary antibodies (in PBS-T, 
with 1% skimmed milk for anti-Goat and anti-Mouse antibodies). GAPDH has been used as housekeeping 
protein. 
 
Primary antibodies and dilutions: 
Rabbit anti-MARK4L (not commercial; GenScript Corporation) 1: 5,000 
Goat anti-MARK4S* (Abcam)     1: 1,250 
Mouse anti-GAPDH* (ab8245; Abcam, Cambridge, UK)  1: 10,000  
 
Secondary antibodies and dilutions: 
Goat anti-Rabbit IgG-HRP (Santa Cruz Biotechnology)  1: 25,000  
Goat anti-Mouse IgG-HRP (Santa Cruz Biotechnology)  1: 25,000 
Donkey anti-Goat IgG-HRP (Santa Cruz Biotechnology)  1: 25,000 
Anti-biotin, HRP-linked antibody (Cell Signaling)   1: 6,250 
 
The secondary antibodies are HRP30-conjugated. 
The anti-biotin antibody allows detecting the biotinylated protein ladder. 
 
After 4 washes in PBS-T and 2 washes in PBS, protein detection was performed: the membranes were 
covered with a peroxide/enhancer solution (Protein detection system from GeneSpin, Milano, Italy) for 5 
min, and exposed to an Amersham Hyperfilm ECL plate (GE Healthcare, Waukesha, WI, USA), then 
developed by Dental X-Ray developer and Dental X-Ray fixer (Kodak; Bagnolet Cedex, France).  
 
6.1 Semi-quantitative analysis 
To compare MARK4L and S proteins expression in different samples, we carried out a relative quantification 
analysis, based on densitometry using GAPDH as normalizer (to correct differences in lysate loading, 
protein transfer and antibody binding).  
For quantification, a low exposure time was chosen, so that the signal intensity on the plate was directly 
proportional (in the linear range) to the emitted signal intensity.  
                                                          
30 Horse Radish Peroxidase 
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TIF images were acquired from plates using a scanner and analyzed with the Image J software, a public 
domain JAVA image processing program (http://rsbweb.nih.gov/ij) allowing the analysis of one-dimensional 
electrophoretic gel or membrane using a simple graphical method 
(http://rsbweb.nih.gov/ij/docs/menus/analyze.html). Briefly, each lane (including both MARK4L and 
GAPDH bands) was selected and lane profile plots were generated, displaying a two-dimensional graph 
reporting peaks corresponding to gel bands (on the X-axis) and their relative pixel intensities (on the Y-axis). 
After manually subtracting the background (necessary step to compare different plates), the area of each 
peak of interest (in square pixels) was measured.  
For each sample MARK4L/GAPDH or MARK4S/GAPDH ratio was calculated to normalize data (Figure 1).  
MARK4L and S expression levels shown in this thesis are referred to the NS sample, chosen as reference, 
whose value was set as 1. 
 
 
Figure 1: [upper] Example of WB membrane semi-quantitative analysis with Image J software. The box indicates one of the lanes, 
selected to generate its profile plot in Image J [lower] In the profile plot the TARGET (MARK4L or S) and GAPDH peaks are indicated 
and background subtracted by manually defining the peak boundaries with a line. M=molecular weight standards.  
 
7. IMMUNOFLUORESCENCE 
ImmunoFluorescence (IF) has been performed to visualize the subcellular localization of MARK4 both in 
non treated and transfected cells. IF was carried out in all samples in parallel. 
Cells were seeded on glass chamber slides and processed at the end of transfection period (72-120 hours).  
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To optimize centrosomes visualization, cells were washed in PEM buffer to stabilize microtubules (0.1% 
Triton X-100, 80 mM PIPES31, pH 6.9, 5 mM EGTA32, 1 mM MgCl2), and fixed with methanol for 12 min at -
20°C for 12 min at RT . Permeabilization was performed by 0.1% Triton X-100 in PBS for 3 min.  
Alternatively, cells were washed in PBS, fixed with methanol for 12 min at -20°C or with 4% 
paraformaldehyde (PFA) in PBS for 12 min at RT; permeabilization was obtained with PBS 0.1% or 0.5% 
Triton X-100 for 3 min.  
In all samples, blocking was performed by incubation with 5% bovine serum albumin (BSA) in PBS-Tween20 
for 30 min, before incubation with primary antibodies. 
 
Primary antibodies and dilutions: 
Rabbit anti-MARK4L (not commercial; GenScript)    1:200 
Rabbit anti-MARK4S (M4947, Sigma)     1:200 
Mouse anti-γ tubulin (clone GTU-88; Sigma)  1:200 
Mouse anti-nucleolin (C23 D-6, Santa Cruz Biotechnology)   1:200 
Mouse anti-nucleophosmin (B23, clone FC82291, Sigma)   1:200 
 
Antibodies were diluted in PBS with 0.1% Tween20, and 1% goat serum33 (Sigma) and incubated overnight 
at 4°C in a humidified chamber. Nucleolin and nucleophosmin were alternatively incubated for 1 hour at 
RT.  
After three 10’ washes in PBS, slides were incubated with secondary antibodies diluted in PBS, 0.1% 
Tween20, 2% BSA and 1% goat serum, for 1 hour at RT in a dark humidified chamber.  
  
 Secondary antibodies and dilutions: 
 Goat anti-rabbit IgG-FITC34 (Sigma)  1:250  
 Goat anti-mouse IgG-TRITC35 (Sigma)   1:200 
 
After 3 PBS washes of 10’ each, slides were mounted with DAPI /antifade (Vector Labs, Burlingame, CA, 
USA) and examined using an Olympus IX51 inverted fluorescence microscope, equipped with an Olympus 
DP71 super high-resolution colour digital camera and U-MNIBA2 excitation 460/490 (FITC), U-MWIG3 
excitation 530/550 (TRITC) and U-MNU2 (DAPI) filters.  
Images were acquired and processed using the F-View II-Bund-cell F software (Olympus, Tokyo, Japan). 
 
                                                          
31 1,4-piperazinediethanesulfonic acid. 
32 Ethylene Glycol Tetraacetic Acid. 
33 To reduce non-specific binding, the serum of the animal where the secondary antibodies are raised (goat) is added. 
34 Fluorescein IsoThioCyanate. 
35 TetramethylRhodamine IsoThioCyanate. 
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8. CELL CYCLE ANALYSIS BY FLUORESCENCE-ACTIVATED CELL SORTING  
Cell cycle analysis has been performed by flow cytometry. Flow cytometry relevant features are 
summarized in BOX 2. 
 
Sample preparation 
Harvested cells (by Trypsin/EDTA 0.05% in PBS) were counted, centrifuged 7’ at 1200 rpm and washed with 
1 mL of PBS. The pellet has been accurately resuspended on ice in Saline GM solution (1 mL) by an insulin 
syringe with 22G needle. 3 mL of 96% EtOH have been added drop by drop, while vortexing, to fix cells 
preventing aggregation and to obtain a final concentration of 70% EtOH. Fixed samples were preserved at 
4°C before staining. 
Saline GME solution 
Glucose   1.1 g/L 
NaCl   8 g/L 
KCl   0.4 g/L 
Na2HPO4.2H2O   0.2 g/L (0.39 g/L *12 H2O) 
KH2PO4   0.15 g/L 
EDTA   0.2 g/L (0.5 mM) 
 
Propidium Iodide Staining 
Fixed samples were centrifuged at 1200 rpm 10’, washed with PBS, then resuspended in 2 mL of 25 μg/mL 
IP solution and PBS (1:1) and incubated O.N. at 4°C before the analysis with cytofluorimeter. 25uL of RNAse 
A (1mg/mL) were also added. 
Fluorescence intensity of cells stained with Propidium Iodide (PI) correlates with the amount of DNA: since 
DNA content (and fluorescence intensity) duplicates during S phase, it is possible to discriminate G0, G1 and 
G2/M. 
During cytofluorimetric analysis, doublet discrimination has been performed to avoid artifacts due to 
aggregation (doublets) of G0/G1 cells: as doublets have the same amount of DNA of a single cell in the G2/M 
phase, they have to be necessarily excluded. We acquired 10000 events for each sample.  
Cell cycle distribution has been evaluated by FACS-Calibur flow cytometer (Becton Dickinson), characterized 
by an argon laser, with 488 nm wavelength and constant 15mV power.  
 
DNA – Phospho Histone H3 staining 
In eukaryotes,phosphorylation of histone H3 is tightly correlated with chromosome condensation during 
both mitosis and meiosis, so that immunostaining with phospho-specific antibodies in mammalian cells, 
counterstained with Propidium Iodide, can reveal the fraction of G2/M phases correspondent to mitosis. 
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 After fixation, cells were centrifuged at 1200 rpm for 10 minutes in PBS 5% FBS to favor pelletting, then 
washed with PBS 1% BSA (optional). Pellets were incubated in 0.25% Triton X 100 for 5 minutes on ice. 2 mL 
of cold PBS 1% BSA were added and cells were centrifuged at 1200 rpm 10’. Samples were incubated O.N. 
at 4°C in agitation with 200 μL of Anti Phospo H3 (1 μg /200 μL of PBS 1% BSA - Upstate code #06-570, 200 
μg/μL). After incubation, cells were washed with PBS 1% BSA and centrifuged at 1200 rpm 10’.  
Cells were incubated with FITC goat anti-rabbit antibody (Jackson Lab cat 111-096-003) 0.5/0.7 μg in 200 μL 
1% BSA at RT for 1 hour in agitation. After washing with PBS 1% BSA, cells were resuspended in 2 mL of 
Propidium Iodide solution (2.5 μg/mL in PBS) and 25 uL of RNAse (1mg/mL) for at least 60’ at RT. 
Samples were analyzed at cytofluorimeter (Excitation 488-635 nM; emission 530-620-661716 nm). 
 
9. APOPTOSIS TEST 
Apoptosis Test was performed by Membrane Permeability/Dead Cell Apoptosis Kit with YO-PRO®-1 and PI 
for flow cytometry (Invitrogen).  
Apoptosis is a regulated process of cell death, distinguished from necrosis by characteristic morphological 
and biochemical changes. During apoptosis cells undergo compaction and fragmentation of the nuclear 
chromatin, shrinkage of the cytoplasm and loss of membrane asymmetry. 
During apoptosis the cytoplasmic membrane becomes slightly permeant to some dyes, such as the green 
fluorescent YO-PRO®-1 dye that, combined with PI, provide a sensitive indicator for apoptosis, similarly to 
what happened by Annexin V/ IP staining. 
 
Transfected cells have been harvested at the end of RNAi treatment and washed in cold PBS; cell density 
has been adjusted to ~1 × 106 cells/mL in PBS. For each assay, 1 mL has been used. 
After adding 1 μL of YO-PRO®-1 solution and 1 μL PI solution (as instructed by manufacturer), cell 
suspensions were incubated on ice for 20–30 minutes. 
 After staining with YOPRO®-1 dye and PI, apoptotic cells show green fluorescence, dead cells show red and 
green fluorescence, and live cells show little or no fluorescence. These populations can easily be 
distinguished by a flow cytometer that uses the 488 nm line of an argon-ion laser for excitation.  
Within 1–2 hours after incubation period, stained cells were analyzed by flow cytometry, using 488 nm 
excitation with green fluorescence emission for YO-PRO®-1 (i.e., 530/30 bandpass) and red fluorescence 
emission for propidium iodide (i.e.,610/20 bandpass), gating on cells to exclude debris. Standard 
compensation was performed using single-color stained cells. 
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BOX 2 – FLOW CYTOMETRY 
 
Figure 2: Schematic overview of a typical flow cytometer setup 
 
One of the fundamentals of flow cytometry is the ability to measure the properties of individual particles. 
When a sample in solution is injected into a flow cytometer, the particles are randomly distributed in three-
dimensional space. To be correctly interrogated by the detection system, the sample must therefore be 
ordered into a stream of single particles by the fluidics system: a central channel/core, through which the 
sample is injected, is enclosed by an outer sheath that contains faster flowing fluid and creates a massive 
drag effect on the narrowing central chamber. This process, known as “hydrodynamic focusing”, creates a 
single file of particles. Under optimal conditions (laminar flow) the fluid in the central chamber will not mix 
with the sheath fluid. After hydrodynamic focusing, each particle passes through one or more beams of 
light. Light scattering or fluorescence emission (if the particle is labeled with a fluorochrome) provides 
information about the particle’s properties. 
Two different types of light source can be used in flow citometry: xenon/mercury arc lamps or lasers. 
Principal emission wave lengths (λ) of a mercury arc lamp are 313, 334, 365, 405, 435, 546 and 578 nm, 
while xenon lamps are characterized by a uniform emission all over the light spectrum: using specific filters 
it is possible to select the desired λ. 
Otherwise, argon lasers show a consistent stability in emission and a very high monochromaticity, 
optimizing signal-noise ratio. Moreover, differently from mercury lamp, this lasers have a very intense 
emission at 488 nm, Fluorescein Isothiocyanate excitation band, the most used fluorochrome in IF. 
The light scattered in the forward direction, typically up to 20o offset from the laser beam’s axis, is collected 
by a lens known as the forward scatter channel (FSC): its intensity roughly equates to the particle’s size and 
can also be used to distinguish between cellular debris and living cells. 
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Light measured approximately at a 90o angle to the excitation line is called side scatter. The side scatter 
channel (SSC) provides information about the granular content within a particle. Both FSC and SSC are 
unique for every particle, and a combination of the two may be used to differentiate different cell types in 
a heterogeneous sample. 
Fluorescence measurements taken at different wavelengths can provide quantitative and qualitative data 
about fluorochrome-labeled cell surface receptors or intracellular molecules such as DNA and cytokines. 
Flow cytometers use separate fluorescence channels (FL-) to detect light emitted. The number of detectors 
will vary according to the machine and its manufacturer. Detectors are either silicon photodiodes 
(commonly used to measure forward scatter when the signal is strong) or photomultiplier tubes (PMTs), 
more sensitive instruments and ideal for scatter and fluorescence readings. 
The specificity of detection is controlled by optical filters, which block certain wavelengths while 
transmitting (passing) others. There are three major filter types: ‘Long pass’ filters allow through light 
above a cut-off wavelength; ‘short pass’ permit light below a cut-off wavelength and ‘band pass’ transmit 
light within a specified narrow range of wavelengths. All these filters block light by absorption. 
Dichroic filters/mirrors are filters placed at a 45o angle to the oncoming light, with two functions: to pass 
specified wavelengths in the forward direction and to deflect blocked light at a 90o angle. To detect 
multiple signals simultaneously, the precise choice and order of optical filters will be an important 
consideration. 
When light hits a photodetector, the voltage of the small current generated has an amplitude proportional 
to the total number of light photons received by the detector. This voltage is then amplified by a series of 
linear or logarithmic amplifiers, and by analog to digital convertors (ADCs), into electrical signals large 
enough (5–10 volts) to be plotted graphically: Log amplification is normally used for fluorescence studies 
because it expands weak signals and compresses strong signals, resulting in a distribution that is easy to 
display on a histogram. Linear scaling is preferable where there is not such a broad range of signals e.g. in 
DNA analysis. 
The measurement from each detector is referred to as a ‘parameter’ (e.g. forward scatter, side scatter or 
fluorescence). The data acquired in each parameter are known as ‘events’ and refer to the number of cells 
displaying the physical feature or marker of interest. 
Flow cytometers are necessarily paired with a computer for data acquisition and analysis, with the 
possibility to measure different parameters simultaneously and a graphical output known as “cytogram”. 
The operator can fix a threshold value and define an “electronic gate”, to exclude irrelevant events (debris, 
spurious events) or to select the cell population of interest, without recurring to physical cell sorting. It is 
also possible to acquire and memorize a list of parameters simultaneously and to recall the data 
afterwards, making the opportune correlations. [Rahman M – Introduction to Flow Cytometry] 
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1. MARK4 dsRNA INTERNALIZATION 
Before investigating MARK4 function by RNAi, we verified the internalization of dsRNAs by Cy3-
Luciferase siRNA with Lipofectamine RNAiMax, by using the two cell systems under study, GBM 
cell lines and fibroblasts. Samples visualization demonstrated a good capture of Cy3 siRNA with 
both reverse and forward transfection (Figure 1). 
 
Figure 1 Cy3 siRNA homogeneously localizes in the cytoplasm of G-32 and fibroblasts cells 24 hours after 
transfection, while the culture medium does not show the presence of free fluorescent marker. 
 
2. ESTIMATION OF MARK4L HALF-LIFE  
We estimated MARK4L half-life, in the attempt to define 
the length of silencing. Experiments were performed by 
CHX method on the GBM MI-60 cell line. As shown in the 
WB, MARK4L protein starts to decrease 120 hours after CHX 
treatment (Figure 2). Thus we decided to prolong silencing 
experiments at least until 120 hours. 
 Figure 2 MARK4L protein levels after CHX treatment  
(final concentration 100ug/uL) 
3. OPTIMIZATION OF MARK4 SILENCING  
To optimize the knockdown by anti-MARK4S+L and anti-MARK4S, we tested different 
concentrations of both dsRNAs on GBM cell lines and fibroblasts under study. Real Time PCR, with 
NS as reference sample, has been used to check the knockdown. 
A final concentration of 60 nM of anti-MARK4S+L siRNA #1089 showed the most efficient 
knockdown of both MARK4 transcripts. Differently, siRNA #1090, targeting exon 18, was less 
efficient for MARK4L silencing, while the combination of different concentrations of siRNAs #1089 
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and #1090 showed a very good silencing of MARK4S but worked sub-optimally for MARK4L (Figure 
3a,b).  
 
Figure 3 Transcript levels of MARK4L (a) and MARK4S (b) in the MI60 GBM cell line after anti -
MARK4S+L siRNAs, at different concentrations and combinations. (Histograms: Light grey = 
siRNA #1089; Medium grey = siRNA #1090; Dark grey = #1089 and #1090 combinations). 
Silencing efficiency was estimated by comparing expression levels of silenced samples with NS 
(control), which expression is, by convention, equal to 1 (horizontal grey arrow). 
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Optimization experiments with anti-MARK4S siRNA demonstrated that a final concentration of 
60nM of siRNA #10 was the most efficient to MARK4S silencing, without significantly influence 
MARK4L expression levels. In contrast, anti-MARK4S #11 and anti-MARK4S #17 (alone or 
combined with other siRNAs) despite having a good efficiency for MARK4S silencing, altered 
MARK4L expression levels (Figure 4a,b). 
 
Figure 4 Transcript 
levels of MARK4L (a) 
and MARK4S (b) after 
anti-MARK4S siRNAs 
with different dsRNAs 
concentrations and 
combinations, tested on 
fibroblasts (Histograms: 
Light grey = Stealth 
siRNA #10; Medium 
grey = Stealth siRNA 
#1090; Black = Stealth 
siRNA #17; squared 
pattern = combinations 
of stealth siRNAs). 
Silencing efficiency was 
estimated by comparing 
expression levels of 
silenced samples with 
NS (control), which 
expression is, by 
convention, equal to 1 
(horizontal grey arrow). 
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4. EVALUATION OF MARK4 KNOCKDOWN 
Once the optimal concentrations of MARK4 dsRNAs were fixed, we evaluated MARK4L and S 
expression levels by Real Time PCR 48 and 120 hours after silencing. 
We found that anti-MARK4S+L siRNA on G-32 and fibroblasts was very efficient: >85% of MARK4S 
and >75% of MARK4L transcripts were silenced in both cellular samples. Conversely, anti-MARK4S 
siRNA showed that >95% of MARK4S transcript was silenced, although a decrease of MARK4L 
(45%) was also detected in G-32 GBM cell line (figure 5). 
  
Figure 5 Graphical representation of MARK4L (blue) and MARK4S (green) transcripts after anti-MARK4S+L and 
anti-MARK4S siRNAs, evaluated by Real Time PCR (Mean expression levels observed in at least three 
independent silencing experiments, with standard deviations). Silencing efficiency was estimated by comparing 
expression levels of silenced samples with NS (control), which expression is, by convention, equal to 1 (red 
arrow). 
 
MARK4S and L silencing has also been verified by WB, and the specific bands have been quantified 
by semi-quantitative densitometric analysis (Figure 6a, b). It is worth noticing that MARK4S protein 
decreases after both anti-MARK4S+L and anti-MARK4S siRNAs, in G-32 as well as in fibroblasts, 
according to Real Time RT-PCR results, while MARK4L protein levels are comparable to the control 
(NS) values, in contrast with Real Time data.  
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Figure 6 (a) WB of MARK4S and MARK4L 120 hours after anti-MARK4S and anti-MARK4S+L siRNA; b) 
densitometric quantification of MARK4L (blue) and MARK4S (green) proteins.  
After MARK4S silencing, the S isoform is reduced of 80% in G-32 and 60% in fibroblasts (white arrows), 
while after anti-MARK4S+L siRNA (grey arrows) the decrease of MARK4S isoform is less evident. In contrast, 
G-32 and fibroblasts don’t show a decrease of the L isoform after both anti-MARK4S (black arrows ), and 
anti-MARK4S+L (black and white arrows) siRNAs. 
 
5. EFFECTS OF MARK4 KNOCKDOWN ON CELLULAR MORPHOLOGY  
MARK4 depleted cells (G-32 and fibroblasts) showed aberrant cellular morphology already 72 
hours post-transfection. G-32 cells appeared polygonal or rounded and fibroblasts lost their typical 
spindle-shaped morphology, appearing shorter and polygonal (figure 7). The effects of MARK4 
depletion on G-32 and fibroblasts morphology were more evident after anti-MARK4S+L siRNA, 
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which also caused a significant reduction of mitotic cells. Images were acquired by Olympus IX51 
inverted microscope, equipped with Olympus DP71 super high-resolution colour digital camera.  
 
 
Figure 7 Comparison between non-treated (NT), Non Specific (NS) and silenced cells morphology: 
after knockdown of both MARK4 isoforms, cellular shape of G-32 GBM cell line and fibroblasts 
appear strikingly altered. 
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6. EFFECTS OF MARK4 KNOCKDOWN ON APOPTOSIS 
Apoptosis has been investigated after anti-MARK4S+L siRNA by cytometric analysis. Results 
showed an increase of necrotic, but not of apoptotic cells, in both the G-32 cell line and in 
fibroblasts (Figure 8). 
 
 
Figure 8 Cytofluorimetric analysis on apoptosis: MARK4 silencing does not induce apoptosis (no variations are 
shown in the lower-right panel of the diagrams), even though an increase in necrotic cells is present (upper 
left panel) most likely due to the cytotoxic effect of silencing as reported in M&M. NS=non specific  
 
7. EFFECTS OF MARK4 KNOCKDOWN ON CENTROSOMES AND NUCLEOLI  
To evaluate the effects of MARK4 silencing on centrosomes structure and number, we performed 
IF using MARK4S and γ-tubulin antibodies. G-32 and fibroblasts treated with anti-MARK4S or anti-
MARKS+L siRNA showed similar IF results. As a general trend, we observed that most of cells 
showed the centrosome duplicated, positioned apically to the nucleus (the centrosome duplicates 
during the G1/S phase). Conversely, control samples showed centrosomes in all centrosome-cycle 
phases (Figure 9). Furthermore MARK4 depleted cells showed a strong reduction in mitoses 
number, and the few ones observable displayed multipolar spindles, spindles without 
microtubules (MTs) nucleation and spindles misalignment (Figure 10). 
Even though MARK4S silencing was verified by Real Time RT-PCR and WB, after IF, a residual signal 
of the protein was still visible at centrosomes. 
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Figure 9 IF on centrosomes of G-32 cell line and fibroblasts. After MARK4 silencing, both samples show most of cells 
with the duplicated centrosome apical to the nucleus (arrows), as expected in G1-S phase. NS samples show 
centrosomes either in G0 -G1 phase (a), G1-S (b) or G2 -M (c). Nuclei are DAPI counterstained. MARK4S (green) and γ- 
Tubuline (red) 
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Figure 10 G-32 aberrant mitoses after MARK4 knockdown. Multipolar spindles (A and B); Quadripolar 
spindle with only two nucleating centrosomes (C); Mis-aligned and/or multipolar spindles (D, E, F and G.) 
 
We evaluated MARK4 silencing on nucleoli at 72, 96 and 120 hours, obtaining homogeneous 
results. IF was carried out with MARK4L, nucleolin or nuclephosmin antibodies. After anti-
MARK4S+L and anti-MARK4S siRNA, MARK4L signals were stronger than in control samples, but 
not detectable in some nucleoli which were, on the contrary, marked with nucleolin or 
nuclephosmin (Figure 11). Counterstaining with nucleolin or nuclephosmin gave concordant 
results.  
 
Figure 11 IF on nucleoli of G-32 GBM cell line 96 hours after silencing. After both anti-MARK4S and anti-MARK4S+L 
siRNA, MARK4L signal is more intense than control samples (arrows), despite few nucleoli are negative after both 
isoforms knockdown (asterisks). Otherwise NS samples show MARK4L overlapping nucleolin signals. MARK4L 
(green) nucleolin (red). 
 
IF on fibroblasts, after MARK4 depletion, showed an unexpected signal of MARK4L around nucleoli 
(not shown). Given that in our previous study [Magnani, In press] we did not observe a MARK4L 
nucleolar/perinucleolar association in normal cells, we wondered whether this result reflected 
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MARK4 silencing or might be an artifact due to IF treatments. To verify this hypothesis, we applied 
IF on fibroblasts after MARK4 RNAi, using different combinations of fixation and permeabilization, 
as shown in table 1.  
Permeabilization Fixation
MARK4L 
signal
0,1% Triton X-100 MetOH - -
0,1% Triton X-100
Paraformaldehyde 
4% in PBS
- -
0,5% Triton X-100 MetOH + -
0,5% Triton X-100
Paraformaldehyde 
4% in PBS
+ +
 
Table 1 Different combinations of IF conditions tested: intensity of MARK4L signals 
inside nucleoli is indicated in the third column: “- -“ = absent; “+ -“ = weak; “+ +” = high 
signal 
 
We observed that the combination of 0,5% Triton X-100 and cold paraformaldehyde abolished the 
perinucleolar MARK4L signals in fibroblasts deprived of MARK4; however, signals of MARK4L, 
counterstained with nucleolin or nucleophosmin, were present inside nucleoli 96 hours after 
silencing and showed a higher intensity than those in control samples (Figure 12a). Interestingly, 
after 120 hours of MARK4S silencing, MARK4L, nucleolin and nucleophosmin were no more visible 
in a small fraction of nucleoli. After MARK4S+L silencing, much more nucleoli were unlabeled by 
MARK4L, nucleolin and nucleophosmin, compared to NS controls. Concordant IF results have been 
obtained in at least three independent silencing experiments. 
 
 
Figure 12a IF on nucleoli of fibroblasts. After 96h of both MARK4 silencing, MARK4L overlaps nucleolin signals that 
appear more intense than in NS. MARK4L (green) and nucleolin ( red). 
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Figure 12b IF images on nucleoli of fibroblasts after 120 hours of silencing. Anti-MARK4S siRNA shows some 
nucleoli negative for MARK4L and nucleolin, while much more nucleoli are unlabeled after siRNA anti-
MARK4S+L. MARK4L (green) and Nucleolin ( red). (A) 60X objective, (B) 20X objective  
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8. EFFECTS OF MARK4 SILENCING ON CELL CYCLE PROGRESSION 
Since we observed that MARK4 silencing affected the mitosis, apparently along with the 
centrosome cycle, in both G-32 and fibroblasts, we investigated, by flow cytometry, the cell cycle 
progression after MARK4 knockdown. 
We performed a bi-parametric cytometric analysis by Propidium Iodide and Phospho histone H3 (a 
mitotic marker) assay. G-32 and fibroblasts were plated and treated during their exponential 
growth phase.  
After 72 hours of silencing, an inhibitory effect on G-32 growth was already evident, when cells 
looked almost steady if compared with NS control (Figure 13a).  
To determine if G-32 cell growth was blocked at a specific phase of the cell cycle and if MARK4S 
rather than MARK4S+L depletion affected mitotic progression, we performed histone H3/DNA 
flow cytometry analysis. Since 48 hours after transfection with anti-MARK4S+L siRNA (but not with 
anti-MARK4S siRNA), G-32 undergoes a significant decrease in mitotic cells: from 1.90% of NS to 
0.17% in silenced cells (figure 13b – panels D and F) that was maintained up to 72 hours. G-32 DNA 
histograms reveal that 72 hours of MARK4S depletion determined a slight increase in G1 fraction, 
with a concomitant decrease of G2/M and S phase cells (figure 13c – panels G,H). A different effect 
on cell cycle was detected with MARK4S+L siRNA: after 48 hours an increase of S fraction (33% vs. 
21% of NS sample) and a decrease of G2/M were observed, due to a delay in entering from G1 to S 
phase (figure 13c – panels D,F,G,I). Overall, these data support the hypothesis that MARK4 
silencing, may induce G1 arrest by blocking the G1/S transition. 
 
 
Figure 13a Growth Curve of G-32 GBM cell line. After both anti-MARK4S (red) and anti-MARK4S+L 
(green) siRNA, proliferation rate is reduced if compared to NS sample (blue). 
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Figure 13b Evaluation of G-32 GBM cell line mitotic fractions by double staining with propidium iodide and 
anti-phospho histone H3. Mitotic events are double-positive and gated by a rectangle. 24 hours after 
plating, no differences in mitotic events are observable between NS and silenced samples. After 48 and 72 
hours, antiMARK4S+L siRNA induces a significant decrease in the mitotic fraction. 
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Figure 13c DNA content analysis of G-32 cell line. Both MARK4 silencing determines a reduction of G2/M cell cycle 
phase already after 48 hours (panels E and F). anti-MARK4S si-RNA reduces S phase cells 72 hours after transfection 
(panel H), while silencing of both isoforms determines a delay in moving from G1 to S phases (panel F and I). 
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Fibroblasts growth kinetics showed after 72 and 120 hours of antiMARK4S and MARK4S+L siRNA a 
reduction of proliferation rate (figure 14a). MARK4 deprived fibroblasts showed after 72 hours a 
significant reduction of the mitotic fraction (Figure 14b, panels E, F, H, I) and of the S phase (Figure 
14 c, panels E, F, H, I), that became more pronounced after 120 hours of silencing. In particular, 
after 72h of MARK4S+L siRNA, we observed in silenced fibroblasts an increase of G1 (90% vs. 76% 
of NS - Figure 14c, panels D,F) and a decrease of S phase (2% vs. 16% - Figure 14c panels D,F). After 
120 hours, a G2/M reduction was observed (2% vs. 12% of NS), while the S phase of silenced and 
NS samples was comparable (Figure 14c, panels G,I). Concordantly, anti-MARK4S siRNA showed 
similar cell cycle profiles (Figure 14c, panels E, H). In addition, since mitotic events are significantly 
reduced after MARK4 silencing, it is interesting to point out that G2/M component of silencing cells 
is mainly imputable to G2 cells and not to mitotic events, which frequence is higher in NS sample 
(figure 14 b and c). 
The slight progressive decrease in the S phase-fraction in NS cells (Figure 14c, panels A,D,G), is 
probably due to cell contact inhibition, also inferred by optical microscopy (Figure 7) and by the 
cell curve, with a growth arrest 72 hours after plating (figure 14a).  
 
 
 
Figure 14a Growth Curve of fibroblasts. After antiMARK4S (red) and anti-MARK4S+L (green) siRNA, 
proliferation is slower than in NS sample (blue)  
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Figure 14b Evaluation of fibroblasts mitotic fraction by double staining with propidium iodide and anti-
phospho histone H3. Mitotic events are double-positive and gated by a rectangle. 24hours after plating, no 
differences in mitotic events are observed between NS and silenced samples. After 72 and 120 hours, of 
antiMARK4S and antiMARK4S+L siRNA a significant decrease in mitotic fraction is observed. Moreover, 
silenced fibroblasts show a reduction of cells in the S phase, arrowed by  (see also Figure 14c). 
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Figure 14c DNA content analysis of fibroblasts. Both MARK4 silencing determines a significant reduction of S-phase 
cell count already after 72 hours, that is maintained at 120 hours. The G2/M phase is instead reduced only after anti-
MARK4S+L siRNA. 
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We undertook this study to highlight the functional impact of MARK4 gene in glioma and in normal 
cells and to assess if there is a distinct role for its L and S isoforms, with respect to their subcellular 
localization. 
Given that both isoforms of MARK4 have been found associated to centrosomes and midbody, in 
glioma as well as in normal cells, we previously suggested that the kinase might exert its function 
throughout all phases of the cell cycle. Moreover, the additional nucleolar localization of MARK4L 
in tumor cells, suggested that the L variant has isoform-specific functions and interactions (with 
nucleolar components) in tumors [Magnani, In press]. The dual nature of MARK4 has also been 
pinpointed by the S and L expression profiling in glioma, GBM-derived cell lines and neural stem 
cells, and the balance of the two isoforms has been foreseen as a potential target of dysregulation 
in glial tumors. We wondered whether the predominant expression in glioma of MARK4L, variant 
of a protein involved in microtubule dynamics, may concur to mitotic errors during gliomagenesis. 
To investigate MARK4 function, we set up RNAi experiments on the G-32 glioblastoma cell line and 
on fibroblasts. Due to the lack of information on MARK4 half-life, to plan a proper silencing time-
lapse, we performed cycloheximide (CHX) treatment on the selected cell systems and obtained 
evidence of a long (>96 hours) MARK4L half-life. On the basis of the observation of a decreased 
protein level after 120 hours of CHX, we monitored MARK4 silencing at 72, 96 and 120 hours. 
The only commercially available and validated dsRNAs contemporaneously silence both isoforms 
of MARK4. Hence, to obtain the specific silencing of S isoform, we designed a custom panel of 3 
dsRNAs, taking advantage of the retention of exon 16, skipped in MARK4L transcript, and which is 
the target of the anti-MARK4S siRNAs. Unfortunately, it was not possible to design a dsRNA 
specific for MARK4L, since the sequence of this transcript is partially shared with MARK4S, thus 
not ensuring a specific target effect. 
Real Time RT-PCR demonstrated a good silencing efficiency of both MARK4S and L mRNAs (>70%). 
However, while silencing of the S isoform was confirmed by WB, the L protein still persisted after 
120 hours of silencing, (in contrast to the CHX experiments). This let us hypothesize that the 
protein detected in WB could be the fraction pre-existing to the RNAi treatment, hard to be 
depleted because of its long half-life. In addition, since RNAi acts by inducing degradation of the 
target mRNA, preventing its translation, a residual pre-existing protein cannot be abolished.  
An overview summarizing the effects of MARK4 knockdown on cell morphology, centrosomes, 
nucleoli and cell cycle is depicted in Figure 1. 
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Figure 1 Overview of MARK4 silencing effects on mitosis (a); cell cycle (b); cell morphology (c), nucleoli (d) and 
centrosome (e). Growth curves of the treated cells are reported too. 
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We showed that MARK4 depletion determines alterations in both G-32 and fibroblasts cell shape, 
supporting MARK4 role in cytoskeleton organization. Morphologic aberrations are usually a 
consequence of cytoskeleton defects, compatible with the known role of MARK proteins in 
influencing MTs dynamics. In accordance, PAR proteins, orthologs of MARKs in lower eukaryotes, 
are involved in establishing cell polarity and embryonic segmentation: Par-1 has been described in 
C. Elegans as a regulator of stability, density, and/or organization of the microtubule cytoskeleton 
[Kemphues 1988].  
MARK4 silencing particularly affected the centrosome cycle. Silenced G-32 glioblastoma cells and 
fibroblasts displayed most of the cells with duplicated centrosomes, apical to the nucleus as 
hallmark of G1/S transition. Differently, control cells showed centrosomes in all phases of the 
centrosome cycle. Accordingly, cell cycle analysis showed an increase of G1 cells fraction and a 
strong reduction of mitoses in both treated tumor cells and fibroblasts: the few observable 
mitoses showed huge aberrations, supporting a role for MARK4 in regulating MTs and MAPs, 
during the mitotic process. 
In particular, silencing of both isoforms of MARK4 heavily reduced mitotic cells in G-32 GBM cell 
line, while MARK4S knockdown effects were weaker. On the contrary, in fibroblasts, both anti-
MARK4S and anti-MARK4S+L siRNA determined a significant decrease of mitotic fraction and S-
phase, with a concomitant increase of G1, compatible with G1 arrest. Thus, cells are unable to 
overcome the G1/S checkpoint and to proceed through the S phase, in agreement with the 
observed arrest at G1/S of centrosome cycle after silencing. (Centrosome initiates the duplication 
at the transition from G1 to S phase, and subsequently migrates to cell poles to prepare the mitotic 
process - Nigg 2002). 
The inability of the duplicated centrosome to separate and migrate to the cell poles raises the 
hypothesis of the involvement of motor proteins, such as myosin II, which inhibition has been 
reported to block the separation and positioning of duplicated centrosomes [Rosenblatt 2004]. 
Interestingly, MARK4 is known to co-immunoprecipitate with a complex containing α, β, and γ 
tubulin, and non-muscle myosin and actin [Trinczek 2004; Brajenovic 2004].  
14-3-3 proteins are other putative interactors of MARK4, acting as pivot in various cellular 
processes, including mitotic exit and cytokinesis, and G1/S transition, and are regulated, as MARK4, 
by PKC, MAPK and GSK3 [Brajenovic 2004; Timm 2008]. The overall observations let us to 
hypothesize that MARK4 depletion may perturb phosphorylation pathways mostly implicated at 
G1/S checkpoint (Figure 2). 
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Figure 2 Diagram of the main actors of cell cycle checkpoints regulation. MARK4 may act, likely as positive regulator, 
at the G1/S checkpoint. 
 
Even though MARK4S silencing has been verified by Real Time PCR and WB, a residual signal, 
compatible with a pre-existing MARK4S protein that cannot be abolished by RNAi, was still visible 
in G1/S arrested, likely non functional centrosomes  
 
Examining MARK4 silencing effects on nucleolus, we observed that MARK4L is also detectable in 
fibroblasts nucleoli, apparently in contrast with previous data that depicted MARK4L as a nucleolar 
tumor marker [Magnani 2011, In press]. The presence of the protein in nucleoli of normal cells has 
been investigated after modifications of IF protocols with a stronger fixation/permeabilization 
procedure. Thus the differential localization previously observed between normal and tumor cells 
can be explained by the intrinsic difficulty to unmask the L isoform of MARK4 in the nucleolus of 
normal cells using standard protocols.  
MARK4 silencing on G-32 did not point out differences between anti-MARK4S and MARK4S+L 
siRNAs, as both showed an increase of MARK4L signal intensity, even though some nucleoli 
appeared silenced. This finding agrees with the detection of MARK4L in WB after silencing. 
In contrast, MARK4-silenced fibroblasts showed several nucleoli unlabeled with MARK4L, in 
particular when both isoforms were targeted. Interestingly, MARK4L+S-depleted nucleoli were 
also deprived of nucleolin or nucleophosmin, suggesting that MARK4L silencing in fibroblasts could 
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affect the most relevant structural components of the nucleolus. In keeping with this view, we 
have previously observed that RNAse treatment abolishes both MARK4L and nucleophosmin, 
suggesting MARK4L interaction with a ribonucleoproteic complex in the nucleolus.  
It has been reported that nucleolin depletion, even not affecting centrosome duplication, leads to 
alterations of cell cycle, with increase of G2/M population, and a significant decrease of mitotic 
index, compatible with a G2 arrest [Ugrinova 2007]; nuclephosmin downregulation is instead 
thought to be responsible of a delays in mitotic entry [Amin 2008]. 
A suggestive hypothesis is that the observed differences between G-32 and fibroblasts nucleoli 
after MARK4 silencing might be imputable to diverse MARK4L conformations, post-translational 
modifications or interactions in the two cell systems. 
The nucleolar fraction of MARK4L could represent the end point of nucleolar sequestration, as 
already known for other proteins that, at different phases of the cell cycle, can be internalized into 
the nucleolus, and usually show a distinctive state of phosphorylation/dephosporylation, 
suggesting a role for this compartment and its proteins in checkpoint signaling. Significant 
examples include: i) Cdc14, a phosphatase critical for promoting mitosis exit, which is kept inactive 
in the nucleolus until the onset of anaphase, thus preventing the premature onset of mitotic exit; 
ii) the p53 inhibitor Mdm2, which is sequestered in response to the activation of the Myc 
oncoprotein or replicative senescence, allowing p53 to become active and iii) Pch2, required for 
halting meiotic cell-cycle progression in response to recombination and chromosome synapsis 
defects [Sirri 2008, Visintin 2000, Pederson 2011]. 
 
Furthermore, the concomitant alterations in both centrosomal and nucleolar compartments after 
MARK4 silencing suggest a putative role of the protein in the regulation of the Nucleus - 
(Nucleolus) - Centrosome (NC) axis [Gant Luxton 2011]. The NC - axis is oriented and paired with 
polarization and migration axis of many cell types, including fibroblasts. Microtubules are the 
major players in organizing a dynamic structure along NC - axis, regulating nuclear movement 
during cell migration and polarization. Since MARK4 cooperates with microtubules network, its 
depletion likely interferes with the correct activity of the NC-axis orientation. It is worth pointing 
out that like MARK4, its orthologous Par6α localizes at the centrosome and is essential for its 
positioning during neuronal migration [Solecki 2004]. Cdc42, already identified as a MARK4 
potential interactor [Brajenovic 2004; Angrand 2006] is implied in controlling NC - axis formation 
during fibroblasts migration, thanks to its effect on Par6. Par3, another member of PAR family, 
Discussion 
 
 
78 
 
associates with dynein light intermediate chains (LIC2), also required for centrosome centration 
[Schmoranzer 2009]. Other known interactors of MARK4, such as actin and myosin II, are implied 
in defining the NC - axis, together with cell-cell junctions mediated by cadherin. These effectors 
have been found crucial during cell division [Gant Luxton 2011]. 
In addition, knockdown of nucelophosmin has been demonstrated to determine dramatic changes 
in nuclear morphology and defects of cytoskeleton structure, particularly of microtubule 
polymerization, leading to hypothesize a functional interaction between the nucleolus and the 
microtubule network. Such functional connection may also apply to MARK4, as it associates with 
both centrosome and nucleolus. 
All together, MARK4 RNAi experiments showed that alterations of cell morphology, centrosome 
and cell cycle progression and mitosis are more evident when both isoforms of MARK4 are 
silenced.  
These findings suggest that the functions of the two isoforms are strictly intermingled, as inferable 
by their common subcellular localization. The reciprocal influence between MARK4S and L 
isoforms has also been highlighted by the reduction of MARK4L mRNA levels following MARK4S 
specific silencing in G-32 cell line (Results - Figure 5)  
In conclusion, we addressed MARK4 function by silencing S isoform or both S+L in two cellular 
systems, one prototypical of normal cells (i.e fibroblasts) and a GBM cell line (G-32), derived from 
a stage IV glioma, which exemplifies a tumor pathology at its most advanced stage. Glioma cell 
lines and tumor biopsies have been intensively investigated and characterized in our laboratory in 
the last few years and have been instrumental in the characterization of the MARK4 gene. 
Both interference approaches showed that the two isoforms synergistically cooperate in the main 
MARK4 function of guarding the G1/S checkpoint: a subtle unbalance of the S/L ratio may direct 
the switch to terminal differentiation or contribute to tumor development and progression. The 
driving causes of disequilibrium between S and L are currently unknown: one promising research 
line is currently under way in our lab, and addresses the fine-tuned regulation of alternative 
splicing [Luco & Misteli 2011] and its disruption in tumors [Venables 2006; Grosso 2008]. 
Interestingly a role for alternative splicing in chromosome instability has been recently envisaged 
[Lopez-Saavedra & Herrera 2010] linking a feature typical of glial tumours to dysregulation of 
MARK4S/MARK4L ratio. 
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1. CONCLUSIONS  
 
 
After MARK4 depletion we observed: 
 Arrest of the cell cycle at the G1 phase with significant reduction of the mitotic index 
 Arrest of centrosome cycle at G1/S checkpoint  
 A more evident effect on cell proliferation, mitosis and centrosomal anomalies when 
silencing both isoforms, suggestive of merging functions for the two isoforms  
 Perturbation of nucleolus structure , also abolishing nucleolin or nucleophosmin  
when MARK4L is depleted  
 MARK4L nucleolar localization also in normal cells, i.e. fibroblasts.  
 
2. PERSPECTIVES 
 
 Definitely confirm that the G2-M proportion of cells observed after silencing is mainly 
imputable to G2 events by performing a cytometry assay using CycB1 staining, as 
complementary to phospho H3 assay (G2 cells are CycB1 positive, while mitotic cells are 
CycB1 negative).  
 Complete MARK4 functional study with overexpression assays by constructs already 
generated in our laboratory, inducing specific overexpression of the two isoforms.  
 Deepen splicing regulation of MARK4 mRNA, identifying the putative regulators and 
the implied signaling pathways. 
 Investigate other MARK4 interactors by co-immunoprecipitation.  
 Verify the phosphorylation status of the two isoforms in both tumor and normal cells, 
more specifically looking for differences in post-translational modifications and/or 
interactions in the two cell systems. 
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